

Eleftherios P Diamandis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3156576/publications.pdf>

Version: 2024-02-01

865
papers

44,349
citations

2213

99
h-index

5677

162
g-index

887
all docs

887
docs citations

887
times ranked

35604
citing authors

#	ARTICLE	IF	CITATIONS
1	Theranos revisited: the trial and lessons learned. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 4-6.	1.4	6
2	From the amyloid hypothesis to the autoimmune hypothesis of Alzheimer's disease. <i>Diagnosis</i> , 2022, 9, 280-281.	1.2	2
3	Stable flow-induced expression of KLK10 inhibits endothelial inflammation and atherosclerosis. <i>ELife</i> , 2022, 11, .	2.8	19
4	The mother of all battles: Viruses vs humans. Can humans avoid extinction in 50-100 years?. <i>Open Life Sciences</i> , 2022, 17, 32-37.	0.6	0
5	Lifestyle Modification Is Appropriate as Primary Prevention. <i>JAMA Cardiology</i> , 2022, 7, 231.	3.0	1
6	Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 88-89.	1.4	2
7	Ultrasensitive assay for saliva-based SARS-CoV-2 antigen detection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 771-777.	1.4	11
8	Convoluting molecular maze of neprilysin. <i>Diagnosis</i> , 2022, 9, 508-510.	1.2	1
9	Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1116-1123.	1.4	3
10	Electronic field effect detection of SARS-CoV-2 N-protein before the onset of symptoms. <i>Biosensors and Bioelectronics</i> , 2022, 210, 114331.	5.3	16
11	Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line. <i>Clinical Proteomics</i> , 2022, 19, 14.	1.1	3
12	Multi Cancer Early Detection by Using Circulating Tumor DNA - The Galleri Test. Reply to Klein et al. The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. <i>Diagnostics</i> 2021, 11, 2171; <i>Diagnostics</i> , 2022, 12, 1244.	1.3	10
13	Cancer Screening Companies Are Rapidly Proliferating: Are They Ready for Business?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1146-1150.	1.1	6
14	COVID-19: from an acute to chronic disease? Potential long-term health consequences. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 297-310.	2.7	224
15	The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 1-16.	2.7	21
16	Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?. <i>BJU International</i> , 2021, 127, 654-664.	1.3	2
17	Alzheimer Disease Pathogenesis: The Role of Autoimmunity. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 756-764.	0.6	19
18	Proteomic Profiling of the Human Tissue and Biological Fluid Proteome. <i>Journal of Proteome Research</i> , 2021, 20, 444-452.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Inappropriate extrapolations abound in fecal microbiota research. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e307-e308.	1.4	2
20	COVID-19 and the Le Chatelier's principle. <i>Diagnosis</i> , 2021, .	1.2	2
21	Assay requirements for COVID-19 testing: serology vs. rapid antigen tests. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e348-e350.	1.4	1
22	Plasma Protein Profiling by Proximity Extension Assay Technology Reveals Novel Biomarkers of Traumatic Brain Injury—A Pilot Study. <i>Journal of Applied Laboratory Medicine</i> , The, 2021, 6, 1165-1178.	0.6	4
23	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <i>JCO Precision Oncology</i> , 2021, 5, 485-491.	1.5	5
24	Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1353-1361.	1.4	25
25	Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden. <i>F1000Research</i> , 2021, 10, 509.	0.8	6
26	Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. , 2021, 9, e002140.		10
27	From Camille Néel, to Apollonian and the Dionysian scientists. <i>Diagnosis</i> , 2021, .	1.2	0
28	Novel severe traumatic brain injury blood outcome biomarkers identified with proximity extension assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1662-1669.	1.4	2
29	An overview of mental health during the COVID-19 pandemic. <i>Diagnosis</i> , 2021, 8, 403-412.	1.2	57
30	Commensals can become pathobionts. <i>Journal of Clinical Periodontology</i> , 2021, 48, 1491-1492.	2.3	1
31	Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100155.	2.5	36
32	Do <i>Prevotella copri</i> and <i>Blastocystis</i> promote euglycaemia?. <i>Lancet Microbe</i> , The, 2021, 2, e565-e566.	3.4	6
33	CSF neurofilament light may predict progression from amnesic mild cognitive impairment to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 107, 78-85.	1.5	5
34	Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. <i>Diagnostics</i> , 2021, 11, 2171.	1.3	26
35	Putative Concussion Biomarkers Identified in Adolescent Male Athletes Using Targeted Plasma Proteomics. <i>Frontiers in Neurology</i> , 2021, 12, 787480.	1.1	3
36	The growing problem of predatory publishing: a case report. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, e51-e53.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Prognostic urinary miRNAs for the assessment of small renal masses. <i>Clinical Biochemistry</i> , 2020, 75, 15-22.	0.8	18
38	Searching for prognostic biomarkers for small renal masses in the urinary proteome. <i>International Journal of Cancer</i> , 2020, 146, 2315-2325.	2.3	21
39	Kallikrein-related peptidases protein expression in lymphoid tissues suggests potential implications in immune response. <i>Clinical Biochemistry</i> , 2020, 77, 41-47.	0.8	5
40	Potential risks in fecal microbiota transplantation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, e95.	1.4	0
41	Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2020, 13, 125.	1.3	3
42	Utility of a Fifth-Generation Ultrasensitive Prostate-Specific Antigen Assay for Monitoring Prostate Cancer Patients after Radical Prostatectomy with 3 Years of Follow-Up. <i>Clinical Chemistry</i> , 2020, 66, 1329-1338.	1.5	3
43	News Stories and Medical Breakthroughs. <i>journal of applied laboratory medicine, The</i> , 2020, 5, 613-615.	0.6	0
44	Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1. <i>Science Signaling</i> , 2020, 13, .	1.6	10
45	The Outcomes of Scientific Debates Should Be Published: The Arivale Story. <i>journal of applied laboratory medicine, The</i> , 2020, 5, 1070-1075.	0.6	5
46	Mutations in normal tissues—some diagnostic and clinical implications. <i>BMC Medicine</i> , 2020, 18, 283.	2.3	19
47	Can a Broad Molecular Screen Based on Circulating Tumor DNA Aid in Early Cancer Detection?. <i>journal of applied laboratory medicine, The</i> , 2020, 5, 1372-1377.	0.6	18
48	Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients. , 2020, 2, e0189.		44
49	Peptidomic Analysis of Urine from Youths with Early Type 1 Diabetes Reveals Novel Bioactivity of Uromodulin Peptides In Vitro. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 501-517.	2.5	29
50	Drug-Resistant Bacteremia after Fecal Microbiota Transplant. <i>New England Journal of Medicine</i> , 2020, 382, 1960-1962.	13.9	14
51	Urinary proteomics links keratan sulfate degradation and lysosomal enzymes to early type 1 diabetes. <i>PLoS ONE</i> , 2020, 15, e0233639.	1.1	6
52	Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1651-1653.	1.4	12
53	P4 medicine or O4 medicine? The perils of population wide, asymptomatic disease screening. <i>Clinical Biochemistry</i> , 2020, 77, 62.	0.8	1
54	Mass Spectrometry-Based Assay for Targeting Fifty-Two Proteins of Brain Origin in Cerebrospinal Fluid. <i>Journal of Proteome Research</i> , 2020, 19, 3060-3071.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2568-2574.	1.1	26
56	Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study. <i>Neurobiology of Aging</i> , 2020, 93, 97.e1-97.e7.	1.5	17
57	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020, 9, 337.	0.8	6
58	Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. <i>F1000Research</i> , 2020, 9, 732.	0.8	2
59	Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. <i>F1000Research</i> , 2020, 9, 732.	0.8	2
60	Antibody tests for COVID-19: drawing attention to the importance of analytical specificity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1144-1145.	1.4	22
61	Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET- $A\beta$ load and cerebrospinal fluid $A\beta$ in a pilot study of Alzheimer's disease. <i>Neuroscience Letters</i> , 2020, 731, 135078.	1.0	6
62	Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1844-1851.	1.9	13
63	New approaches for detecting cancer with circulating cell-free DNA. <i>BMC Medicine</i> , 2019, 17, 159.	2.3	21
64	Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer. <i>BMC Cancer</i> , 2019, 19, 696.	1.1	7
65	A proteome-wide immuno-mass spectrometric identification of serum autoantibodies. <i>Clinical Proteomics</i> , 2019, 16, 25.	1.1	15
66	A Key to Success Is the Key that Opens and Closes the Lab Door. <i>Journal of Applied Laboratory Medicine</i> , 2019, 4, 135-136.	0.6	1
67	Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1807-1823.	2.5	31
68	Playing the game of scientific publishing. <i>Clinical Biochemistry</i> , 2019, 73, 118-120.	0.8	1
69	Gut microbiotas and immune checkpoint inhibitor therapy response: a causal or coincidental relationship?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 58, 18-24.	1.4	13
70	Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET. <i>Translational Neurodegeneration</i> , 2019, 8, 25.	3.6	11
71	Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1875-1881.	1.4	20
72	Cell-free DNA Analysis in Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 501-502.	13.9	12

#	ARTICLE	IF	CITATIONS
73	The democratization of scientific publishing. BMC Medicine, 2019, 17, 12.	2.3	9
74	Proteome-wide onco-proteogenomic somatic variant identification in ER-positive breast cancer. Clinical Biochemistry, 2019, 66, 63-75.	0.8	3
75	Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1737-1743.	1.4	7
76	Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry. Clinical Proteomics, 2019, 16, 23.	1.1	15
77	P4 Medicine or O4 Medicine? Hippocrates Provides the Answer. journal of applied laboratory medicine, The, 2019, 4, 108-119.	0.6	14
78	Androgen receptor: A promising therapeutic target in breast cancer. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 200-223.	2.7	23
79	Benefits and harms of wellness initiatives. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1494-1500.	1.4	3
80	Biochemical pathways mediated by <scp>KLK</scp>6 protease in breast cancer. Molecular Oncology, 2019, 13, 2329-2343.	2.1	12
81	The plasma peptides of breast versus ovarian cancer. Clinical Proteomics, 2019, 16, 43.	1.1	16
82	Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass. American Journal of Pathology, 2019, 189, 2366-2376.	1.9	12
83	Simpson's paradox in proof-of-concept studies. Nature Medicine, 2019, 25, 1640-1640.	15.2	11
84	Theranos: Almost Complete Absence of Laboratory Medicine Input. journal of applied laboratory medicine, The, 2019, 3, 749-752.	0.6	2
85	Identification of TEX101-associated Proteins Through Proteomic Measurement of Human Spermatozoa Homozygous for the Missense Variant rs35033974*. Molecular and Cellular Proteomics, 2019, 18, 338-351.	2.5	26
86	Can Grail find the trail to early cancer detection?. Clinical Chemistry and Laboratory Medicine, 2019, 57, 403-406.	1.4	9
87	Discovery of novel plasma biomarker ratios to discriminate traumatic brain injury. F1000Research, 2019, 8, 1695.	0.8	7
88	Putative autoantibodies in the cerebrospinal fluid of Alzheimer's disease patients. F1000Research, 2019, 8, 1900.	0.8	13
89	Advocate cultivation of academic ethics: why is it necessary?. F1000Research, 2019, 8, 1830.	0.8	2
90	Advocate cultivation of academic ethics: why is it necessary?. F1000Research, 2019, 8, 1830.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Is it time to abandon the Nobel Prize?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1196-1197.	1.4	1
92	Manfred Schmitt (1947–2018). <i>Biological Chemistry</i> , 2018, 399, 923-924.	1.2	0
93	The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer. <i>Biological Chemistry</i> , 2018, 399, 973-982.	1.2	4
94	Comparison of five cell-free DNA isolation methods to detect the <i>EGFR</i> T790M mutation in plasma samples of patients with lung cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e243-e246.	1.4	9
95	Proteinases and their receptors in inflammatory arthritis: an overview. <i>Nature Reviews Rheumatology</i> , 2018, 14, 170-180.	3.5	45
96	Athletes beware before throwing towels to audiences. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e82-e82.	1.4	1
97	Targeted Mass Spectrometry-Based Assays for Relative Quantification of 30 Brain-Related Proteins and Their Clinical Applications. <i>Journal of Proteome Research</i> , 2018, 17, 2282-2292.	1.8	24
98	Benign and malignant scientific irreproducibility. <i>Clinical Biochemistry</i> , 2018, 55, 1-2.	0.8	10
99	Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach. <i>Journal of Proteomics</i> , 2018, 182, 12-20.	1.2	57
100	Young scientists and Clinical Biochemists need to develop superior negotiating skills. <i>Clinical Biochemistry</i> , 2018, 54, 142.	0.8	2
101	Differentiating Psoriatic Arthritis From Psoriasis Without Psoriatic Arthritis Using Novel Serum Biomarkers. <i>Arthritis Care and Research</i> , 2018, 70, 454-461.	1.5	46
102	The plasma peptides of ovarian cancer. <i>Clinical Proteomics</i> , 2018, 15, 41.	1.1	33
103	The plasma peptidome. <i>Clinical Proteomics</i> , 2018, 15, 39.	1.1	22
104	Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 466-479.	2.7	15
105	Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. <i>BMC Medicine</i> , 2018, 16, 166.	2.3	181
106	Introduction to the Special Collection "Beating Cancer with Early Detection: A Seasoned Idea with New Insights. <i>Journal of Applied Laboratory Medicine</i> , The, 2018, 3, 155-158.	0.6	0
107	Circulating Tumor DNA for Early Cancer Detection. <i>Journal of Applied Laboratory Medicine</i> , The, 2018, 3, 300-313.	0.6	25
108	Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1945-1953.	1.4	15

#	ARTICLE	IF	CITATIONS
109	Expression profile of human tissue kallikrein 15 provides preliminary insights into its roles in the prostate and testis. <i>Clinical Biochemistry</i> , 2018, 59, 78-85.	0.8	5
110	Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer. <i>Clinical Biochemistry</i> , 2018, 58, 108-115.	0.8	7
111	The meteoric rise and dramatic fall of Theranos: lessons learned for the diagnostic industry. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1443-1446.	1.4	17
112	Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. <i>F1000Research</i> , 2018, 7, 189.	0.8	3
113	Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 9.	3.0	17
114	Discovery of a Human Testis-specific Protein Complex TEX101-DPEP3 and Selection of Its Disrupting Antibodies. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2480-2495.	2.5	25
115	Hubris and Sciences. <i>F1000Research</i> , 2018, 7, 133.	0.8	2
116	Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression. <i>F1000Research</i> , 2018, 7, 1012.	0.8	34
117	A miRNA-based classification of renal cell carcinoma subtypes by PCR and <i>in situ</i> hybridization. <i>Oncotarget</i> , 2018, 9, 2092-2104.	0.8	22
118	Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. <i>F1000Research</i> , 2018, 7, 189.	0.8	3
119	Functional proteomic profiling reveals KLK13 and TMPRSS11D as active proteases in the lower female reproductive tract. <i>F1000Research</i> , 2018, 7, 1666.	0.8	2
120	Functional proteomic profiling reveals KLK13 and TMPRSS11D as active proteases in the lower female reproductive tract. <i>F1000Research</i> , 2018, 7, 1666.	0.8	4
121	An integrated proteomic and peptidomic assessment of the normal human urinome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 237-247.	1.4	28
122	Proteomic and peptidomic analysis of human sweat with emphasis on proteolysis. <i>Journal of Proteomics</i> , 2017, 155, 40-48.	1.2	53
123	Stable Isotope Labeling with Amino Acids (SILAC)-Based Proteomics of Primary Human Kidney Cells Reveals a Novel Link between Male Sex Hormones and Impaired Energy Metabolism in Diabetic Kidney Disease. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 368-385.	2.5	13
124	Kallikrein-related peptidase expression in odontogenic cysts and tumors: An immunohistochemical comparative study. <i>Journal of Investigative and Clinical Dentistry</i> , 2017, 8, e12256.	1.8	1
125	Direct-to-Consumer Testing. <i>Clinical Chemistry</i> , 2017, 63, 635-641.	1.5	10
126	The current peer review system is unsustainable-awaken the paid reviewer force!. <i>Clinical Biochemistry</i> , 2017, 50, 461-463.	0.8	8

#	ARTICLE	IF	CITATIONS
127	Variant peptide detection utilizing mass spectrometry: laying the foundations for proteogenomic identification and validation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1291-1304.	1.4	9
128	Human tissue Kallikreins: Blood levels and response to radiotherapy in intermediate risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 427-432.	0.3	10
129	Wellness Initiatives: Benefits and Limitations. <i>Clinical Chemistry</i> , 2017, 63, 1063-1068.	1.5	2
130	Effect of age on serum prostate-specific antigen in women. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, e271-e272.	1.4	3
131	The emerging landscape of scientific publishing. <i>Clinical Biochemistry</i> , 2017, 50, 651-655.	0.8	12
132	The Role of Procalcitonin in Diagnosis of Sepsis and Antibiotic Stewardship: Opportunities and Challenges. <i>Clinical Chemistry</i> , 2017, 63, 1436-1441.	1.5	13
133	Biochemical and functional characterization of the human tissue kallikrein 9. <i>Biochemical Journal</i> , 2017, 474, 2417-2433.	1.7	8
134	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	13
135	Urinary adenosine excretion in type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F184-F191.	1.3	46
136	Preclinical evaluation of a TEX101 protein ELISA test for the differential diagnosis of male infertility. <i>BMC Medicine</i> , 2017, 15, 60.	2.3	58
137	Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1574-1581.	1.4	8
138	Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1789-1797.	1.4	14
139	Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 414-432.	2.7	16
140	How to reduce scientific irreproducibility: the 5-year reflection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1845-1848.	1.4	9
141	Discovery of Antimicrobial Peptides in Cervical Vaginal Fluid from Healthy Nonpregnant Women via an Integrated Proteome and Peptidome Analysis. <i>Proteomics</i> , 2017, 17, 1600461.	1.3	15
142	HtrA3 stromal expression is correlated with tumor budding in stage II colorectal cancer. <i>Experimental and Molecular Pathology</i> , 2017, 103, 94-100.	0.9	16
143	Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion. <i>Molecular Oncology</i> , 2017, 11, 1330-1347.	2.1	14
144	Towards personalized tumor markers. <i>Npj Precision Oncology</i> , 2017, 1, 17.	2.3	20

#	ARTICLE	IF	CITATIONS
145	Generation of monoclonal antibodies and development of an immunofluorometric assay for the detection of CUZD1 in tissues and biological fluids. <i>Clinical Biochemistry</i> , 2017, 50, 1168-1174.	0.8	2
146	A new enzyme-linked immunosorbent assay (ELISA) for human free and bound kallikrein 9. <i>Clinical Proteomics</i> , 2017, 14, 4.	1.1	12
147	The Journal Impact Factor is under attack – use the CAPCI factor instead. <i>BMC Medicine</i> , 2017, 15, 9.	2.3	23
148	Study of kallikrein-related peptidase 6 (KLK6) and its complex with $\hat{1}$ -antitrypsin in biological fluids. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1385-1396.	1.4	8
149	How I first met Dr. Morton K. Schwartz. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 910-913.	1.4	0
150	Rafa Nadal federal-The greatest tennis player that ever lived. <i>Clinical Biochemistry</i> , 2017, 50, 977-978.	0.8	2
151	Circulating tumor DNA for personalized lung cancer monitoring. <i>BMC Medicine</i> , 2017, 15, 157.	2.3	10
152	Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2017, 08, .	0.4	18
153	Synovial fluid proteomics in the pursuit of arthritis mediators: An evolving field of novel biomarker discovery. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 495-505.	2.7	26
154	Serum complexed and free prostate specific antigen levels are lower in female elite athletes in comparison to control women. <i>F1000Research</i> , 2017, 6, 1131.	0.8	7
155	Make researchers revisit past publications to improve reproducibility. <i>F1000Research</i> , 2017, 6, 1717.	0.8	8
156	Can circulating tumor DNA be used for direct and early stage cancer detection?. <i>F1000Research</i> , 2017, 6, 2129.	0.8	34
157	Half-Century of Cancer Biomarkers: Lessons from the Past and Projections for the Future. <i>Journal of Applied Laboratory Medicine</i> , The, 2017, 2, 288-290.	0.6	3
158	The Use of Targeted Therapies for Precision Medicine in Oncology. <i>Clinical Chemistry</i> , 2016, 62, 1556-1564.	1.5	10
159	An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma. <i>Journal of Proteomics</i> , 2016, 142, 114-121.	1.2	22
160	Identification of brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and mining of the Human Protein Atlas. <i>Clinical Proteomics</i> , 2016, 13, 11.	1.1	67
161	Significant increase of serum prostate-specific antigen after exercise. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e245-e246.	1.4	2
162	Dynamics of Protein Expression Reveals Primary Targets and Secondary Messengers of Estrogen Receptor Alpha Signaling in MCF-7 Breast Cancer Cells. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2093-2107.	2.5	32

#	ARTICLE	IF	CITATIONS
163	Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine, 2016, 14, 73.	2.3	908
164	Major milestones in translational oncology. BMC Medicine, 2016, 14, 110.	2.3	15
165	Putative functions of tissue kallikrein-related peptidases in vaginal fluid. Nature Reviews Urology, 2016, 13, 596-607.	1.9	21
166	Theranos phenomenon â€“ Part 5: Theranosâ€™™ presentation at the American Association for Clinical Chemistry Annual Conference 2016. Clinical Chemistry and Laboratory Medicine, 2016, 54, e313-e314.	1.4	4
167	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1333-1340.	1.1	35
168	Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multiplatform Targeted Mass Spectrometry Assays. Molecular and Cellular Proteomics, 2016, 15, 2863-2876.	2.5	42
169	CRISPR-Cas9 System: Opportunities and Concerns. Clinical Chemistry, 2016, 62, 1304-1311.	1.5	7
170	Genomic profiling for copy number changes in plasma of ovarian cancer patients â€“ a new era for cancer diagnostics?. BMC Medicine, 2016, 14, 186.	2.3	5
171	Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer. Biological Chemistry, 2016, 397, 1265-1276.	1.2	25
172	Association between <i>Echinococcus granulosus</i> infection and cancer risk â€“ a pilot study in Cyprus. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1955-1961.	1.4	19
173	Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. Clinical Proteomics, 2016, 13, 16.	1.1	24
174	Proteogenomics: Opportunities and Caveats. Clinical Chemistry, 2016, 62, 551-557.	1.5	29
175	Prostate-Specific Antigen as a Marker of Hyperandrogenism in Women and Its Implications for Antidoping. Clinical Chemistry, 2016, 62, 1066-1074.	1.5	9
176	Theranos phenomenon â€“ part 4: Theranos at an International Conference. Clinical Chemistry and Laboratory Medicine, 2016, 54, e243-4.	1.4	7
177	Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?. Clinical Chemistry, 2016, 62, 1054-1060.	1.5	87
178	Cancer dynamics and the success of cancer screening programs. Clinical Chemistry and Laboratory Medicine, 2016, 54, e211-2.	1.4	5
179	A replacement for the testosterone â€œsex gapâ€: Clinical Chemistry and Laboratory Medicine, 2016, 54, e61.	1.4	1
180	Technology-driven diagnostics: From smart doctor to smartphone. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 268-276.	2.7	14

#	ARTICLE	IF	CITATIONS
181	A Word of Caution on New and Revolutionary Diagnostic Tests. <i>Cancer Cell</i> , 2016, 29, 141-142.	7.7	8
182	The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia. <i>Clinical Biochemistry</i> , 2016, 49, 213-218.	0.8	46
183	The question I hate the most. <i>Nature</i> , 2016, 530, 121-121.	13.7	2
184	Kallikrein-related peptidases (KLKs) and the hallmarks of cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 277-291.	2.7	73
185	Theranos phenomenon “ part 3. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e145-6.	1.4	7
186	Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e1-2.	1.4	17
187	The side effects of translational omics: overtesting, overdiagnosis, overtreatment. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 389-96.	1.4	26
188	Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome. <i>American Journal of Cancer Research</i> , 2016, 6, 61-70.	1.4	5
189	Accuracy of Testosterone Concentrations in Compounded Testosterone Products. <i>Journal of Sexual Medicine</i> , 2015, 12, 1381-1388.	0.3	17
190	Dr. Lee Goodglick: A Valuable Collaborator and A Dear Friend. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 335.	0.2	0
191	Application of Modular Therapy for Renoprotection in Experimental Chronic Kidney Disease. <i>Tissue Engineering - Part A</i> , 2015, 21, 1963-1972.	1.6	1
192	Comparative Proteomics of Ovarian Cancer Aggregate Formation Reveals an Increased Expression of Calcium-activated Chloride Channel Regulator 1 (CLCA1). <i>Journal of Biological Chemistry</i> , 2015, 290, 17218-17227.	1.6	26
193	Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics. <i>Journal of Biological Chemistry</i> , 2015, 290, 17762-17775.	1.6	26
194	Effectiveness of the Risk of Malignancy Index and the Risk of Ovarian Malignancy Algorithm in a Cohort of Women With Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 809-814.	1.2	15
195	Peer review as a business transaction. <i>Nature</i> , 2015, 517, 145-145.	13.7	17
196	Collagen Type XII and Versican Are Present in the Early Stages of Cartilage Tissue Formation by Both Redifferentating Passaged and Primary Chondrocytes. <i>Tissue Engineering - Part A</i> , 2015, 21, 683-693.	1.6	33
197	Unleashing the therapeutic potential of human kallikrein-related serine proteases. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 183-202.	21.5	192
198	Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers. <i>Clinical Proteomics</i> , 2015, 12, 1.	1.1	44

#	ARTICLE	IF	CITATIONS
199	Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2015, 113, 484-491.	2.9	27
200	Getting noticed is half the battle. <i>Science</i> , 2015, 349, 206-206.	6.0	2
201	OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery. <i>Oncology Letters</i> , 2015, 9, 418-424.	0.8	13
202	Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	20
203	Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1575-84.	1.4	49
204	Immunocapture-Selected Reaction Monitoring Screening Facilitates the Development of ELISA for the Measurement of Native TEX101 in Biological Fluids*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1517-1526.	2.5	38
205	Preeclampsia: An Old Disease with New Tools for Better Diagnosis and Risk Management. <i>Clinical Chemistry</i> , 2015, 61, 694-698.	1.5	16
206	A Day in the Life of Dr. Bean and How the NIH Is Wasting \$20 Billion per Year. <i>Clinical Chemistry</i> , 2015, 61, 783-784.	1.5	0
207	An enzyme-linked immuno-mass spectrometric assay with the substrate adenosine monophosphate. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 1119-1130.	1.9	7
208	Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers. <i>Clinical Chemistry</i> , 2015, 61, 809-820.	1.5	120
209	The hundred person wellness project and Google's baseline study: medical revolution or unnecessary and potentially harmful over-testing?. <i>BMC Medicine</i> , 2015, 13, 5.	2.3	30
210	Theranos phenomenon: promises and fallacies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 989-93.	1.4	40
211	Bone morphogenetic protein antagonist gremlin-1 regulates colon cancer progression. <i>Biological Chemistry</i> , 2015, 396, 163-183.	1.2	57
212	Build reward system for ace technicians. <i>Nature</i> , 2015, 519, 414-414.	13.7	1
213	Prognostic significance of multiple kallikreins in high-grade astrocytoma. <i>BMC Cancer</i> , 2015, 15, 565.	1.1	20
214	Theranos phenomenon - part 2. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1911-2.	1.4	10
215	A Renin-ssance in Primary Aldosteronism Testing: Obstacles and Opportunities for Screening, Diagnosis, and Management. <i>Clinical Chemistry</i> , 2015, 61, 1022-1027.	1.5	18
216	Theranos promises a new era of preventive health care - but where's the physician?. <i>Clinical Biochemistry</i> , 2015, 48, 1027.	0.8	6

#	ARTICLE	IF	CITATIONS
217	Delineating monoclonal antibody specificity by mass spectrometry. <i>Journal of Proteomics</i> , 2015, 114, 115-124.	1.2	8
218	Toward an integrated pipeline for protein biomarker development. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 677-686.	1.1	56
219	Human kallikrein 10 in surgically removed human pituitary adenomas. <i>Hormones</i> , 2014, 14, 272-9.	0.9	3
220	The role of ubiquitin-binding domains in human pathophysiology. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 280-290.	2.7	6
221	Learning from Siddhartha. <i>Clinical Chemistry</i> , 2014, 60, 429-429.	1.5	0
222	False Biomarker Discovery due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125. <i>Clinical Chemistry</i> , 2014, 60, 381-388.	1.5	38
223	Ovarian Cancer Biomarkers. <i>Advances in Clinical Chemistry</i> , 2014, , 25-77.	1.8	20
224	Present and future of cancer biomarkers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 791-4.	1.4	33
225	Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. <i>Biological Chemistry</i> , 2014, 395, 95-107.	1.2	22
226	A repository for "rare" tumor markers?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 795-7.	1.4	13
227	Mining for single nucleotide variants (SNVs) at the kallikrein locus with predicted functional consequences. <i>Biological Chemistry</i> , 2014, 395, 1037-1050.	1.2	4
228	Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer. <i>Biological Chemistry</i> , 2014, 395, 1075-1086.	1.2	32
229	Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 765-6.	1.4	25
230	Towards identification of true cancer biomarkers. <i>BMC Medicine</i> , 2014, 12, 156.	2.3	30
231	Proteomic analysis of cancer and mesothelial cells reveals an increase in Mucin 5AC during ovarian cancer and peritoneal interaction. <i>Journal of Proteomics</i> , 2014, 103, 204-215.	1.2	13
232	Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts. <i>Molecular Oncology</i> , 2014, 8, 1240-1252.	2.1	25
233	Proteomic signatures of angiogenesis in androgen-independent prostate cancer. <i>Prostate</i> , 2014, 74, 260-272.	1.2	26
234	Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. <i>Acta Neuropathologica</i> , 2014, 127, 633-643.	3.9	120

#	ARTICLE	IF	CITATIONS
235	Tumor Microenvironmentâ€“Released Peptides: Could They Form the Basis for an Early-Diagnosis Breast Cancer Test?. <i>Clinical Chemistry</i> , 2014, 60, 4-6.	1.5	0
236	Collective migration of cancerâ€“associated fibroblasts is enhanced by overexpression of tight junctionâ€“associated proteins claudinâ€“1 and occludin. <i>Molecular Oncology</i> , 2014, 8, 178-195.	2.1	43
237	Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression. <i>Prostate</i> , 2014, 74, 372-380.	1.2	57
238	Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5787-5795.	3.2	115
239	Highlight: The 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases. <i>Biological Chemistry</i> , 2014, 395, 913-914.	1.2	1
240	Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms. <i>Journal of Proteome Research</i> , 2014, 13, 1077-1087.	1.8	60
241	Putative kallikrein substrates and their (patho)biological functions. <i>Biological Chemistry</i> , 2014, 395, 931-943.	1.2	15
242	Identification of Novel Biomarkers of Brain Damage in Patients with Hemorrhagic Stroke by Integrating Bioinformatics and Mass Spectrometry-Based Proteomics. <i>Journal of Proteome Research</i> , 2014, 13, 969-981.	1.8	31
243	What Is Wrong with Clinical Proteomics?. <i>Clinical Chemistry</i> , 2014, 60, 1258-1266.	1.5	23
244	Seminal plasma as a diagnostic fluid for male reproductive system disorders. <i>Nature Reviews Urology</i> , 2014, 11, 278-288.	1.9	159
245	Integrating Meta-Analysis of Microarray Data and Targeted Proteomics for Biomarker Identification: Application in Breast Cancer. <i>Journal of Proteome Research</i> , 2014, 13, 2897-2909.	1.8	22
246	Natriuretic Peptides in Heart Failure. <i>Clinical Chemistry</i> , 2014, 60, 1040-1046.	1.5	21
247	Peptidomics of Urine and Other Biofluids for Cancer Diagnostics. <i>Clinical Chemistry</i> , 2014, 60, 1052-1061.	1.5	64
248	The bifacial role of helminths in cancer: Involvement of immune and non-immune mechanisms. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 138-148.	2.7	12
249	Animal Olfactory Detection of Disease: Promises and Pitfalls. <i>Clinical Chemistry</i> , 2014, 60, 1473-1479.	1.5	9
250	Deciphering the peptidome of urine from ovarian cancer patients and healthy controls. <i>Clinical Proteomics</i> , 2014, 11, 23.	1.1	37
251	Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. <i>Clinical Proteomics</i> , 2014, 11, 27.	1.1	49
252	Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy. <i>SpringerPlus</i> , 2014, 3, 295.	1.2	6

#	ARTICLE	IF	CITATIONS
253	Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 63-84.	2.7	24
254	In-depth proteomic delineation of the colorectal cancer exoproteome: Mechanistic insight and identification of potential biomarkers. <i>Journal of Proteomics</i> , 2014, 103, 121-136.	1.2	25
255	Deciphering the ovarian cancer ascites fluid peptidome. <i>Clinical Proteomics</i> , 2014, 11, 13.	1.1	35
256	Diabetes Induces Lysine Acetylation of Intermediary Metabolism Enzymes in the Kidney. <i>Diabetes</i> , 2014, 63, 2432-2439.	0.3	60
257	Whole Genome Sequencing as a Diagnostic Test: Challenges and Opportunities. <i>Clinical Chemistry</i> , 2014, 60, 724-733.	1.5	64
258	An Emerging Role of TEX101 Protein as a Male Infertility Biomarker. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2014, 25, 9-26.	0.7	10
259	Mechanisms of Androgen-Independent Prostate Cancer. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2014, 25, 42-54.	0.7	39
260	Early outgrowth cells release soluble endocrine antifibrotic factors that reduce progressive organ fibrosis. <i>Stem Cells</i> , 2013, 31, 2408-2419.	1.4	23
261	Fascin-1 is a novel biomarker of aggressiveness in some carcinomas. <i>BMC Medicine</i> , 2013, 11, 53.	2.3	25
262	Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains. <i>Clinical Proteomics</i> , 2013, 10, 5.	1.1	67
263	Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in Down syndrome. <i>Clinical Proteomics</i> , 2013, 10, 2.	1.1	37
264	Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 317-325.	1.4	32
265	Proteomic and Mass Spectrometry Technologies for Biomarker Discovery. , 2013, , 17-37.		19
266	Differential Diagnosis of Azoospermia with Proteomic Biomarkers ECM1 and TEX101 Quantified in Seminal Plasma. <i>Science Translational Medicine</i> , 2013, 5, 212ra160.	5.8	136
267	Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer. <i>Translational Proteomics</i> , 2013, 1, 74-86.	1.2	13
268	Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. <i>BMC Cancer</i> , 2013, 13, 404.	1.1	45
269	The sweet and sour of serological glycoprotein tumor biomarker quantification. <i>BMC Medicine</i> , 2013, 11, 31.	2.3	67
270	Is Early Detection of Cancer with Circulating Biomarkers Feasible?. <i>Clinical Chemistry</i> , 2013, 59, 35-37.	1.5	23

#	ARTICLE	IF	CITATIONS
271	Conquering Cancer in Our Lifetime: New Diagnostic and Therapeutic Trends. <i>Clinical Chemistry</i> , 2013, 59, 1-3.	1.5	20
272	The Long Journey of Cancer Biomarkers from the Bench to the Clinic. <i>Clinical Chemistry</i> , 2013, 59, 147-157.	1.5	127
273	Reflection on the Discovery of Carcinoembryonic Antigen, Prostate-Specific Antigen, and Cancer Antigens CA125 and CA19-9. <i>Clinical Chemistry</i> , 2013, 59, 22-31.	1.5	36
274	Copy Number and Expression Alterations of miRNAs in the Ovarian Cancer Cell Line OVCAR-3: Impact on Kallikrein 6 Protein Expression. <i>Clinical Chemistry</i> , 2013, 59, 296-305.	1.5	15
275	The Proteomic Revolution in Laboratory Medicine. <i>Clinical Biochemistry</i> , 2013, 46, 397-398.	0.8	8
276	Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. <i>Molecular Oncology</i> , 2013, 7, 826-839.	2.1	50
277	Validation of Candidate Protein Biomarkers. , 2013, , 263-271.		3
278	Coupling proteomics and transcriptomics in the quest of subtype-specific proteins in breast cancer. <i>Proteomics</i> , 2013, 13, 1083-1095.	1.3	23
279	Pheochromocytoma. <i>Clinical Chemistry</i> , 2013, 59, 466-472.	1.5	29
280	Design of Tumor Biomarker Monitoring Trials: A Proposal by the European Group on Tumor Markers. <i>Clinical Chemistry</i> , 2013, 59, 52-59.	1.5	37
281	Delineating the synovial fluid proteome: Recent advancements and ongoing challenges in biomarker research. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2013, 50, 51-63.	2.7	19
282	Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. <i>Thrombosis and Haemostasis</i> , 2013, 110, 408-422.	1.8	29
283	Strategies for discovering novel pancreatic cancer biomarkers. <i>Journal of Proteomics</i> , 2013, 81, 126-134.	1.2	63
284	Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. <i>Radiology and Oncology</i> , 2013, 47, 319-329.	0.6	38
285	Pancreatic Cancer. <i>Clinical Chemistry</i> , 2013, 59, 41-46.	1.5	22
286	Induction of Complement C3a Receptor Responses by Kallikrein-Related Peptidase 14. <i>Journal of Immunology</i> , 2013, 191, 3858-3866.	0.4	24
287	Laminin, gamma 2 (LAMC2): A Promising New Putative Pancreatic Cancer Biomarker Identified by Proteomic Analysis of Pancreatic Adenocarcinoma Tissues. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 2820-2832.	2.5	97
288	Nobelitis: a common disease among Nobel laureates?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1573-4.	1.4	6

#	ARTICLE	IF	CITATIONS
289	More discussion on journal impact factor. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2271-2271.	1.4	13
290	Infection and Cancer: Revaluation of the Hygiene Hypothesis. <i>Clinical Cancer Research</i> , 2013, 19, 2834-2841.	3.2	57
291	Kallikrein-Related Peptidase 8. , 2013, , 2792-2798.		1
292	Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1467-76.	1.4	26
293	Determination of an Angiotensin II-regulated Proteome in Primary Human Kidney Cells by Stable Isotope Labeling of Amino Acids in Cell Culture (SILAC). <i>Journal of Biological Chemistry</i> , 2013, 288, 24834-24847.	1.6	37
294	Quantitative Proteomics Reveals That Enzymes of the Ketogenic Pathway Are Associated with Prostate Cancer Progression. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 1589-1601.	2.5	88
295	Kallikrein Cascades in Traumatic Spinal Cord Injury: In Vitro Evidence for Roles in Axonopathy and Neuron Degeneration. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2013, 72, 1072-1089.	0.9	25
296	Proteomic and mass spectrometry technologies for biomarker discovery. , 2013, , 17-37.		9
297	Targeted Selected Reaction Monitoring Mass Spectrometric Immunoassay for Insulin-like Growth Factor 1. <i>PLoS ONE</i> , 2013, 8, e81125.	1.1	40
298	Kallikrein-related Peptidase 13. , 2013, , 2805-2808.		0
299	Kallikrein-related Peptidase 14. , 2013, , 2809-2813.		0
300	Human Tissue Kallikrein 10. , 2013, , 2798-2801.		1
301	Quantitative Analysis of Energy Metabolic Pathways in MCF-7 Breast Cancer Cells by Selected Reaction Monitoring Assay. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 422-434.	2.5	82
302	Autoimmune Diseases: Early Diagnosis and New Treatment Strategies. <i>Clinical Chemistry</i> , 2012, 58, 1510-1514.	1.5	16
303	The Obesity Epidemic. <i>Clinical Chemistry</i> , 2012, 58, 968-973.	1.5	15
304	Searching for New Biomarkers of Renal Diseases through Proteomics. <i>Clinical Chemistry</i> , 2012, 58, 353-365.	1.5	42
305	Revisiting the Complexity of the Ovarian Cancer Microenvironmentâ€”Clinical Implications for Treatment Strategies. <i>Molecular Cancer Research</i> , 2012, 10, 1254-1264.	1.5	40
306	Proteomic Profiling of Androgen-independent Prostate Cancer Cell Lines Reveals a Role for Protein S during the Development of High Grade and Castration-resistant Prostate Cancer. <i>Journal of Biological Chemistry</i> , 2012, 287, 34019-34031.	1.6	65

#	ARTICLE	IF	CITATIONS
307	Ectopic Pregnancy. <i>Clinical Chemistry</i> , 2012, 58, 1278-1285.	1.5	17
308	Cancer-Associated Fibroblasts Drive the Progression of Metastasis through both Paracrine and Mechanical Pressure on Cancer Tissue. <i>Molecular Cancer Research</i> , 2012, 10, 1403-1418.	1.5	437
309	Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. <i>Biological Chemistry</i> , 2012, 393, 391-401.	1.2	36
310	Reference intervals and biological variation for kallikrein 6: influence of age and renal failure. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 931-4.	1.4	5
311	Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors. <i>Biological Chemistry</i> , 2012, 393, 413-420.	1.2	24
312	The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 211-33.	1.4	45
313	Biomarker validation is still the bottleneck in biomarker research. <i>Journal of Internal Medicine</i> , 2012, 272, 620-620.	2.7	7
314	Nucleic Acid Detection Immunoassay for Prostate-Specific Antigen Based on Immuno-PCR Methodology. <i>Clinical Chemistry</i> , 2012, 58, 732-740.	1.5	28
315	Characterization of the seminal plasma proteome in men with prostatitis by mass spectrometry. <i>Clinical Proteomics</i> , 2012, 9, 2.	1.1	31
316	Biomarkers for the diagnosis of new and recurrent prostate cancer. <i>Biomarkers in Medicine</i> , 2012, 6, 587-596.	0.6	21
317	Differential proteomic analysis of bronchoalveolar lavage fluid from lung transplant patients with and without chronic graft dysfunction. <i>Clinical Biochemistry</i> , 2012, 45, 223-230.	0.8	28
318	Performance evaluation of Siemens ADVIA Centaur and Roche MODULAR Analytics E170 Total 25-OH Vitamin D assays. <i>Clinical Biochemistry</i> , 2012, 45, 1485-1490.	0.8	20
319	CUB and zona pellucida-like domain-containing protein 1 (CUZD1): A novel serological biomarker for ovarian cancer. <i>Clinical Biochemistry</i> , 2012, 45, 1543-1546.	0.8	9
320	Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. <i>Tumor Biology</i> , 2012, 33, 1209-1214.	0.8	14
321	Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14. <i>Biological Chemistry</i> , 2012, 393, 421-427.	1.2	18
322	Development of a Multiplex Selected Reaction Monitoring Assay for Quantification of Biochemical Markers of Down Syndrome in Amniotic Fluid Samples. <i>Journal of Proteome Research</i> , 2012, 11, 3880-3887.	1.8	29
323	Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. <i>Pathology Research and Practice</i> , 2012, 208, 104-108.	1.0	30
324	Analysis of Seminal Plasma from Patients with Non-obstructive Azoospermia and Identification of Candidate Biomarkers of Male Infertility. <i>Journal of Proteome Research</i> , 2012, 11, 1503-1511.	1.8	70

#	ARTICLE	IF	CITATIONS
325	Advancing Laboratory Medicine through Innovation: A Tale of Six Inventors. <i>Clinical Chemistry</i> , 2012, 58, 502-510.	1.5	4
326	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. <i>Epigenetics</i> , 2012, 7, 1037-1045.	1.3	42
327	Five Primary Human Pancreatic Adenocarcinoma Cell Lines Established by the Outgrowth Method. <i>Journal of Surgical Research</i> , 2012, 172, 29-39.	0.8	58
328	Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery. <i>BMC Medicine</i> , 2012, 10, 39.	2.3	42
329	The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?. <i>BMC Medicine</i> , 2012, 10, 87.	2.3	152
330	From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. <i>Biomarkers in Medicine</i> , 2012, 6, 613-625.	0.6	24
331	Interlaboratory Reproducibility of Selective Reaction Monitoring Assays Using Multiple Upfront Analyte Enrichment Strategies. <i>Journal of Proteome Research</i> , 2012, 11, 3986-3995.	1.8	62
332	9 Genomic Instability of the KLK-locus in Cancer. , 2012, , 183-200.		0
333	8 Expression of Kallikrein-related Peptidases under (Patho-)Physiological Conditions. , 2012, , 187-250.		0
334	Kallikrein-related peptidase 10 expression in salivary gland tissues and tumours. <i>International Journal of Biological Markers</i> , 2012, 27, 381-388.	0.7	7
335	Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anionâ€exchange chromatography coupled to ELISA and identification by mass spectrometry. <i>Proteomics</i> , 2012, 12, 799-809.	1.3	19
336	Identification and quantification of peptides and proteins secreted from prostate epithelial cells by unbiased liquid chromatography tandem mass spectrometry using goodness of fit and analysis of variance. <i>Journal of Proteomics</i> , 2012, 75, 1303-1317.	1.2	27
337	Kallikrein 6 as a Serum Prognostic Marker in Patients with Aneurysmal Subarachnoid Hemorrhage. <i>PLoS ONE</i> , 2012, 7, e45676.	1.1	17
338	Proteomic Signatures of the Desmoplastic Invasion Front Reveal Collagen Type XII as a Marker of Myofibroblastic Differentiation During Colorectal Cancer Metastasis. <i>Oncotarget</i> , 2012, 3, 267-285.	0.8	90
339	7 Clinical Relevance of Kallikrein-related Peptidases in Ovarian Cancer. , 2012, , 145-166.		6
340	Verification of Male Infertility Biomarkers in Seminal Plasma by Multiplex Selected Reaction Monitoring Assay. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M110.004127.	2.5	99
341	Proteomic Analysis of Seminal Plasma from Normal Volunteers and Post-Vasectomy Patients Identifies over 2000 Proteins and Candidate Biomarkers of the Urogenital System. <i>Journal of Proteome Research</i> , 2011, 10, 941-953.	1.8	154
342	Genomic instability and copyâ€number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. <i>Molecular Oncology</i> , 2011, 5, 48-60.	2.1	21

#	ARTICLE	IF	CITATIONS
343	Kallikrein Protease Involvement in Skin Pathologies Supports a New View of the Origin of Inflamed Itchy Skin. , 2011, , 51-71.		1
344	Kallikrein-Related Peptidase 14 Acts on Proteinase-Activated Receptor 2 to Induce Signaling Pathway in Colon Cancer Cells. American Journal of Pathology, 2011, 179, 2625-2636.	1.9	47
345	Verification of a biomarker discovery approach for detection of Down syndrome in amniotic fluid via multiplex selected reaction monitoring (SRM) assay. Journal of Proteomics, 2011, 74, 2052-2059.	1.2	36
346	Alzheimer Disease: Advances in Pathogenesis, Diagnosis, and Therapy. Clinical Chemistry, 2011, 57, 664-669.	1.5	14
347	The athletes of science. Nature, 2011, 478, 419-419.	13.7	5
348	Mining the malignant ascites proteome for pancreatic cancer biomarkers. Proteomics, 2011, 11, 4551-4558.	1.3	28
349	Pentraxin-3 Is a Novel Biomarker of Lung Carcinoma. Clinical Cancer Research, 2011, 17, 2395-2399.	3.2	108
350	Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer Biomarkers. Molecular and Cellular Proteomics, 2011, 10, M111.008599.	2.5	96
351	Prospective Multi-Institutional Study Evaluating the Performance of Prostate Cancer Risk Calculators. Journal of Clinical Oncology, 2011, 29, 2959-2964.	0.8	86
352	Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients's™ survival. Annals of Oncology, 2011, 22, 1783-1790.	0.6	38
353	Molecular Alterations during Progression of Prostate Cancer to Androgen Independence. Clinical Chemistry, 2011, 57, 1366-1375.	1.5	100
354	Playing the Trumpet. Clinical Chemistry, 2011, 57, 1789-1789.	1.5	0
355	Circulating Cancer Cells and Their Clinical Applications. Clinical Chemistry, 2011, 57, 1478-1484.	1.5	11
356	Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Annals of Oncology, 2011, 22, 877-883.	0.6	36
357	Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens. Cancer Prevention Research, 2011, 4, 365-374.	0.7	256
358	Application of proteomics to prenatal screening and diagnosis for aneuploidies. Clinical Chemistry and Laboratory Medicine, 2011, 49, 33-41.	1.4	11
359	I Detected My Cancer with My Smart Phone. Clinical Chemistry, 2011, 57, 1221-1223.	1.5	2
360	Kallikrein-related Peptidase-8 (KLK8) Is an Active Serine Protease in Human Epidermis and Sweat and Is Involved in a Skin Barrier Proteolytic Cascade. Journal of Biological Chemistry, 2011, 286, 687-706.	1.6	79

#	ARTICLE	IF	CITATIONS
361	Kallikrein-related Peptidase 12 Hydrolyzes Matricellular Proteins of the CCN Family and Modifies Interactions of CCN1 and CCN5 with Growth Factors. <i>Journal of Biological Chemistry</i> , 2011, 286, 25505-25518.	1.6	52
362	Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2083-2093.	1.9	87
363	Immuno-Mass Spectrometry: Quantification of Low-Abundance Proteins in Biological Fluids. <i>Methods in Molecular Biology</i> , 2011, 728, 207-218.	0.4	9
364	The Quest for Renal Disease Proteomic Signatures: Where Should We Look?. <i>Clinical Proteomics</i> , 2010, 6, 45-51.	1.1	2
365	KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. <i>International Journal of Cancer</i> , 2010, 127, 2386-2394.	2.3	13
366	Cartilage tissue enhances proteoglycan retention by nucleus pulposus cells in vitro. <i>Arthritis and Rheumatism</i> , 2010, 62, 3395-3403.	6.7	16
367	The cancer cell secretome: A good source for discovering biomarkers?. <i>Journal of Proteomics</i> , 2010, 73, 1896-1906.	1.2	173
368	Down-regulation of dicer expression in ovarian cancer tissues. <i>Clinical Biochemistry</i> , 2010, 43, 324-327.	0.8	96
369	Nidogen-2: A new serum biomarker for ovarian cancer. <i>Clinical Biochemistry</i> , 2010, 43, 355-361.	0.8	30
370	Direct measurement of serum free testosterone by ultrafiltration followed by liquid chromatography tandem mass spectrometry. <i>Clinical Biochemistry</i> , 2010, 43, 490-496.	0.8	37
371	Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 371-378.	12.8	140
372	Human Kallikrein 14 (Klk14) Expression in Salivary Gland Tumors. <i>International Journal of Biological Markers</i> , 2010, 25, 32-37.	0.7	8
373	Determination of the association of urine prostate specific antigen levels with anthropometric variables in children aged 5-14 years. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2010, 36, 202-208.	0.7	2
374	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. <i>Clinical Chemistry</i> , 2010, 56, e1-e48.	1.5	184
375	Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor. <i>Endocrinology</i> , 2010, 151, 1520-1531.	1.4	194
376	Epigenomics-Based Diagnostics. <i>Clinical Chemistry</i> , 2010, 56, 1216-1219.	1.5	8
377	Can Chemoprevention Reduce the Risk of Prostate Cancer?. <i>Clinical Chemistry</i> , 2010, 56, 1214-1215.	1.5	2
378	Potential role of multiple members of the kallikrein-related peptidase family of serine proteases in activating latent TGF β 21 in semen. <i>Biological Chemistry</i> , 2010, 391, 85-95.	1.2	32

#	ARTICLE	IF	CITATIONS
379	Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid. <i>Biological Chemistry</i> , 2010, 391, 381-90.	1.2	27
380	Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. <i>Biological Chemistry</i> , 2010, 391, 299-310.	1.2	65
381	Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. <i>Biological Chemistry</i> , 2010, 391, 411-23.	1.2	58
382	Prostate Cancer Screening with Prostate-Specific Antigen Testing: More Answers or More Confusion?. <i>Clinical Chemistry</i> , 2010, 56, 345-351.	1.5	21
383	Nipple Aspirate Fluid Proteome of Healthy Females and Patients with Breast Cancer. <i>Clinical Chemistry</i> , 2010, 56, 848-855.	1.5	42
384	Cancer Genomes. <i>Clinical Chemistry</i> , 2010, 56, 1660-1664.	1.5	5
385	Unveiling the Right Side: A Conversation with Pheidias and Pericles about the Elgin Marbles and Other Matters. <i>Clinical Chemistry</i> , 2010, 56, 1042-1044.	1.5	0
386	Early Prostate Cancer Antigen-2: A Controversial Prostate Cancer Biomarker?. <i>Clinical Chemistry</i> , 2010, 56, 542-544.	1.5	14
387	The Time of Young Scientists. <i>Science</i> , 2010, 329, 626-626.	6.0	2
388	Combinatorial Peptide Libraries Facilitate Development of Multiple Reaction Monitoring Assays for Low-Abundance Proteins. <i>Journal of Proteome Research</i> , 2010, 9, 1236-1245.	1.8	64
389	Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. <i>Molecular Oncology</i> , 2010, 4, 496-510.	2.1	135
390	Platform for Establishing Interlaboratory Reproducibility of Selected Reaction Monitoring-Based Mass Spectrometry Peptide Assays. <i>Journal of Proteome Research</i> , 2010, 9, 6678-6688.	1.8	78
391	The Bottleneck in the Cancer Biomarker Pipeline and Protein Quantification through Mass Spectrometry-Based Approaches: Current Strategies for Candidate Verification. <i>Clinical Chemistry</i> , 2010, 56, 212-222.	1.5	165
392	Amniotic Fluid Proteome Analysis from Down Syndrome Pregnancies for Biomarker Discovery. <i>Journal of Proteome Research</i> , 2010, 9, 3574-3582.	1.8	46
393	Cancer Biomarkers: Can We Turn Recent Failures into Success?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1462-1467.	3.0	323
394	The Search for New Prostate Cancer Biomarkers Continues. <i>Clinical Chemistry</i> , 2009, 55, 1277-1279.	1.5	18
395	The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. <i>British Journal of Cancer</i> , 2009, 100, 1659-1665.	2.9	55
396	Differential N-glycosylation of Kallikrein 6 Derived from Ovarian Cancer Cells or the Central Nervous System. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 791-798.	2.5	60

#	ARTICLE	IF	CITATIONS
397	Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 661-669.	2.5	107
398	Effect of Protein Kinase C β Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study. <i>Diabetes Care</i> , 2009, 32, 91-93.	4.3	38
399	Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility. <i>Biological Chemistry</i> , 2009, 390, 921-929.	1.2	23
400	Journal Impact Factor: it will go away soon. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1317-8.	1.4	15
401	Protein Quantification by Mass Spectrometry: Is It Ready for Prime Time?. <i>Clinical Chemistry</i> , 2009, 55, 1427-1430.	1.5	15
402	Longitudinal Cytokine Expression during IMRT for Prostate Cancer and Acute Treatment Toxicity. <i>Clinical Cancer Research</i> , 2009, 15, 5576-5583.	3.2	53
403	Next-Generation Sequencing: A New Revolution in Molecular Diagnostics?. <i>Clinical Chemistry</i> , 2009, 55, 2088-2092.	1.5	18
404	Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. <i>International Journal of Cancer</i> , 2009, 125, 9-14.	2.3	55
405	Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. <i>Clinical Biochemistry</i> , 2009, 42, 426-429.	0.8	29
406	Rapid determination of serum testosterone by liquid chromatography-isotope dilution tandem mass spectrometry and a split sample comparison with three automated immunoassays. <i>Clinical Biochemistry</i> , 2009, 42, 484-490.	0.8	34
407	The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer. <i>Clinical Biochemistry</i> , 2009, 42, 1483-1486.	0.8	6
408	Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition. <i>Clinical Biochemistry</i> , 2009, 42, 1705-1712.	0.8	4
409	Comprehensive Analysis of Conditioned Media from Ovarian Cancer Cell Lines Identifies Novel Candidate Markers of Epithelial Ovarian Cancer. <i>Journal of Proteome Research</i> , 2009, 8, 4705-4713.	1.8	72
410	The Human Kallikrein Gene Family: New Biomarkers for Ovarian Cancer. <i>Cancer Treatment and Research</i> , 2009, 149, 165-187.	0.2	25
411	Functional Roles of Human Kallikrein-related Peptidases. <i>Journal of Biological Chemistry</i> , 2009, 284, 32989-32994.	1.6	193
412	Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. <i>Thrombosis and Haemostasis</i> , 2009, 101, 741-747.	1.8	37
413	Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2746-2758.	2.5	124
414	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. <i>Thrombosis and Haemostasis</i> , 2009, 101, 541-546.	1.8	19

#	ARTICLE	IF	CITATIONS
415	Kallikrein-Related Peptidases: An Emerging Family of Pivotal Players in Epidermal Desquamation and Barrier Function. <i>Basic and Clinical Dermatology</i> , 2009, , 125-148.	0.1	0
416	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. <i>Thrombosis and Haemostasis</i> , 2009, 101, 541-6.	1.8	10
417	Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. <i>Thrombosis and Haemostasis</i> , 2009, 101, 741-7.	1.8	21
418	Prognostic impact of CD68 and kallikrein 6 in human glioma. <i>Anticancer Research</i> , 2009, 29, 3269-79.	0.5	39
419	Human Kallikrein 8 Expression in Salivary Gland Tumors. <i>Head and Neck Pathology</i> , 2008, 2, 169-174.	1.3	24
420	Tissue culture-based breast cancer biomarker discovery platform. <i>International Journal of Cancer</i> , 2008, 123, 2007-2012.	2.3	66
421	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. <i>Clinical Chemistry</i> , 2008, 54, e11-e79.	1.5	539
422	Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. <i>British Journal of Cancer</i> , 2008, 99, 1103-1113.	2.9	90
423	Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2008, 99, 1484-1492.	2.9	61
424	Novel therapeutic applications of cardiac glycosides. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 926-935.	21.5	529
425	Correlation between SPINK5 Gene Mutations and Clinical Manifestations in Netherton Syndrome Patients. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1148-1159.	0.3	79
426	Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). <i>Cancer Science</i> , 2008, 99, 2224-2229.	1.7	24
427	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Quality Requirements1. <i>Clinical Chemistry</i> , 2008, 54, e1-e10.	1.5	128
428	Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10, 11, and 14 in breast cancer cells via a membrane bound androgen receptor. <i>Molecular Oncology</i> , 2008, 1, 413-424.	2.1	17
429	Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. <i>Molecular Oncology</i> , 2008, 2, 250-260.	2.1	16
430	Seminal Plasma Lipocalin-Type Prostaglandin D Synthase: A Potential New Marker for the Diagnosis of Obstructive Azoospermia. <i>Journal of Urology</i> , 2008, 179, 1077-1080.	0.2	43
431	Kallikreins as microRNA targets: an <i>in silico</i> and experimental-based analysis. <i>Biological Chemistry</i> , 2008, 389, 731-738.	1.2	41
432	Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 588-599.	4.3	663

#	ARTICLE	IF	CITATIONS
433	Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer. <i>Clinical Chemistry</i> , 2008, 54, 1951-1960.	1.5	127
434	Product Ion Monitoring Assay for Prostate-Specific Antigen in Serum Using a Linear Ion-Trap. <i>Journal of Proteome Research</i> , 2008, 7, 640-647.	1.8	73
435	Major Role of Human KLK14 in Seminal Clot Liquefaction. <i>Journal of Biological Chemistry</i> , 2008, 283, 19561-19569.	1.6	39
436	Proteomic Analysis of Conditioned Media from the PC3, LNCaP, and 22Rv1 Prostate Cancer Cell Lines: Discovery and Validation of Candidate Prostate Cancer Biomarkers. <i>Journal of Proteome Research</i> , 2008, 7, 3329-3338.	1.8	138
437	Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade. <i>Journal of Biological Chemistry</i> , 2008, 283, 3031-3041.	1.6	56
438	Proteinases as hormones: targets and mechanisms for proteolytic signaling. <i>Biological Chemistry</i> , 2008, 389, 971-982.	1.2	25
439	A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology. <i>Biological Chemistry</i> , 2008, 389, 681-688.	1.2	28
440	Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. <i>Annals of Oncology</i> , 2008, 19, 1271-1277.	0.6	25
441	Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. <i>Biological Chemistry</i> , 2008, 389, 643-651.	1.2	50
442	Substrate specificity determination of mouse implantation serine proteinase and human kallikrein-related peptidase 6 by phage display. <i>Biological Chemistry</i> , 2008, 389, 1097-1105.	1.2	13
443	Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions. <i>Biological Chemistry</i> , 2008, 389, 669-680.	1.2	72
444	Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines. <i>Biological Chemistry</i> , 2008, 389, 1409-1419.	1.2	29
445	Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. <i>Biological Chemistry</i> , 2008, 389, 1513-1522.	1.2	47
446	A Multiparametric Serum Kallikrein Panel for Diagnosis of Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 1355-1362.	3.2	63
447	High Expression of KLK14 in Prostatic Adenocarcinoma Is Associated with Elevated Risk of Prostate-Specific Antigen Relapse. <i>Tumor Biology</i> , 2008, 29, 1-8.	0.8	17
448	Intracellular Signaling Pathways Regulate Hormone-Dependent Kallikrein Gene Expression. <i>Tumor Biology</i> , 2008, 29, 63-75.	0.8	24
449	Mitochondrial Genome Deletion Aids in the Identification of False- and True-Negative Prostate Needle Core Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2008, 129, 57-66.	0.4	48
450	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers. <i>Clinical Chemistry</i> , 2008, 54, 1935-1939.	1.5	46

#	ARTICLE	IF	CITATIONS
451	Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung. <i>Biological Chemistry</i> , 2008, 389, 781-786.	1.2	20
452	Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids. <i>Biological Chemistry</i> , 2008, 389, 747-756.	1.2	31
453	Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. <i>Biological Chemistry</i> , 2008, 389, 739-745.	1.2	68
454	An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. <i>Biological Chemistry</i> , 2008, 389, 773-80.	1.2	17
455	High-Throughput Screening Identifies Cardiac Glycosides as Potent Inhibitors of Human Tissue Kallikrein Expression: Implications for Cancer Therapies. <i>Clinical Cancer Research</i> , 2008, 14, 5778-5784.	3.2	30
456	Utility of Kallikrein-Related Peptidases (KLKs) as Cancer Biomarkers. <i>Clinical Chemistry</i> , 2008, 54, 1600-1607.	1.5	103
457	Substrate specificity determination of mouse implantation serine proteinase and human kallikrein-related peptidase 6 by phage display. <i>Biological Chemistry</i> , 2008, .	1.2	0
458	Proteinases as hormones: targets and mechanisms for proteolytic signaling. <i>Biological Chemistry</i> , 2008, .	1.2	0
459	Expression and Functional Characterization of the Cancer-related Serine Protease, Human Tissue Kallikrein 14. <i>Journal of Biological Chemistry</i> , 2007, 282, 2405-2422.	1.6	91
460	Defining the extended substrate specificity of kallikrein 1-related peptidases. <i>Biological Chemistry</i> , 2007, 388, 1215-1225.	1.2	41
461	Proteomics Analysis of Human Amniotic Fluid. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1406-1415.	2.5	153
462	Discovery of Candidate Tumor Markers for Prostate Cancer via Proteomic Analysis of Cell Culture-Conditioned Medium. <i>Clinical Chemistry</i> , 2007, 53, 429-437.	1.5	75
463	Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1997-2011.	2.5	179
464	A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 6984-6992.	3.2	69
465	Distribution of 15 Human Kallikreins in Tissues and Biological Fluids. <i>Clinical Chemistry</i> , 2007, 53, 1423-1432.	1.5	337
466	Kallikrein-mediated activation of PARs in inflammation and nociception. <i>Inflammation Research</i> , 2007, 56, S499-S502.	1.6	5
467	Enzymatic properties of human kallikrein-related peptidase 12 (KLK12). <i>Biological Chemistry</i> , 2007, 388, 427-35.	1.2	29
468	Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines. <i>Biological Chemistry</i> , 2007, 388, 1113-1119.	1.2	5

#	ARTICLE	IF	CITATIONS
469	Oncopeptidomics: A Useful Approach for Cancer Diagnosis?. <i>Clinical Chemistry</i> , 2007, 53, 1004-1006.	1.5	21
470	Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 4422-4428.	3.2	39
471	Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2007, 13, 1742-1748.	3.2	28
472	A Potential Role for Multiple Tissue Kallikrein Serine Proteases in Epidermal Desquamation. <i>Journal of Biological Chemistry</i> , 2007, 282, 3640-3652.	1.6	235
473	PSA and other tissue kallikreins for prostate cancer detection. <i>European Journal of Cancer</i> , 2007, 43, 1918-1926.	1.3	72
474	Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. <i>Clinica Chimica Acta</i> , 2007, 377, 228-236.	0.5	31
475	Human tissue kallikreins: A road under construction. <i>Clinica Chimica Acta</i> , 2007, 381, 78-84.	0.5	47
476	Human tissue kallikreins: The cancer biomarker family. <i>Cancer Letters</i> , 2007, 249, 61-79.	3.2	157
477	High throughput proteomic strategies for identifying tumour-associated antigens. <i>Cancer Letters</i> , 2007, 249, 110-119.	3.2	66
478	A consolidated catalogue and graphical annotation of dbSNP polymorphisms in the human tissue kallikrein (<i>KLK</i>) locus. <i>Molecular Oncology</i> , 2007, 1, 303-312.	2.1	6
479	New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. <i>Molecular Oncology</i> , 2007, 1, 269-287.	2.1	60
480	Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. <i>Clinical Biochemistry</i> , 2007, 40, 104-110.	0.8	20
481	POINT: EPCA-2: A promising new serum biomarker for prostatic carcinoma?. <i>Clinical Biochemistry</i> , 2007, 40, 1437-1439.	0.8	18
482	An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays. <i>Proteomics - Clinical Applications</i> , 2007, 1, 494-505.	0.8	3
483	Human kallikrein-related peptidase 12: Antibody generation and immunohistochemical localization in prostatic tissues. <i>Prostate</i> , 2007, 67, 1465-1474.	1.2	15
484	Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. <i>British Journal of Cancer</i> , 2007, 96, 362-372.	2.9	43
485	Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. <i>British Journal of Dermatology</i> , 2007, 156, 875-883.	1.4	88
486	Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. <i>Experimental Dermatology</i> , 2007, 16, 513-519.	1.4	182

#	ARTICLE	IF	CITATIONS
487	Ovarian cancer specific kallikrein profile in effusions. <i>Gynecologic Oncology</i> , 2007, 105, 501-507.	0.6	45
488	B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. <i>Gynecologic Oncology</i> , 2007, 106, 334-341.	0.6	67
489	Proteomic Analysis of Human Cervico-Vaginal Fluid. <i>Journal of Proteome Research</i> , 2007, 6, 2859-2865.	1.8	137
490	Assay-specific artificial neural networks for five different PSA assays and populations with PSA ≥ 10 Ång/ml in 4,480 men. <i>World Journal of Urology</i> , 2007, 25, 95-103.	1.2	22
491	Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 7-18.	1.1	41
492	Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. <i>Biological Chemistry</i> , 2006, 387, 1121-8.	1.2	13
493	Somatic Mitochondrial DNA Mutations in Prostate Cancer and Normal Appearing Adjacent Glands in Comparison to Age-Matched Prostate Samples without Malignant Histology. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 312-319.	1.2	60
494	Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics. <i>Advances in Cancer Research</i> , 2006, 96, 23-50.	1.9	64
495	In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. <i>Genomics</i> , 2006, 88, 591-599.	1.3	31
496	Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. <i>Prostate</i> , 2006, 66, 651-659.	1.2	37
497	Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. <i>International Journal of Urology</i> , 2006, 13, 238-243.	0.5	34
498	Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. <i>FEBS Journal</i> , 2006, 273, 2505-2514.	2.2	25
499	Quantification of Eight Tissue Kallikreins in the Stratum Corneum and Sweat. <i>Journal of Investigative Dermatology</i> , 2006, 126, 927-931.	0.3	40
500	Elevated Human Tissue Kallikrein Levels in the Stratum Corneum and Serum of Peeling Skin Syndrome-Type B Patients Suggests an Over-desquamation of Corneocytes. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2338-2342.	0.3	60
501	Proteomic and genomic technologies for biomarker discovery. <i>Clinical Proteomics</i> , 2006, 2, 5-11.	1.1	3
502	Comparison of methods to examine the endogenous peptides of fetal calf serum. <i>Clinical Proteomics</i> , 2006, 2, 67-89.	1.1	9
503	Peptidomics for Cancer Diagnosis: Present and Future. <i>Journal of Proteome Research</i> , 2006, 5, 2079-2082.	1.8	141
504	Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 1296-1302.	0.7	20

#	ARTICLE	IF	CITATIONS
505	Quality of the scientific literature: All that glitters is not gold. <i>Clinical Biochemistry</i> , 2006, 39, 1109-1111.	0.8	13
506	Comparison of protein expression lists from mass spectrometry of human blood fluids using exact peptide sequences versus BLAST. <i>Clinical Proteomics</i> , 2006, 2, 185-203.	1.1	17
507	Prognostic Implications of the Immunohistochemical Expression of Human Kallikreins 5, 6, 10 and 11 in Renal Cell Carcinoma. <i>Tumor Biology</i> , 2006, 27, 1-7.	0.8	34
508	Characterization of Human Kallikreins 6 and 10 in Ascites Fluid from Ovarian Cancer Patients. <i>Tumor Biology</i> , 2006, 27, 227-234.	0.8	25
509	Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer – A Pilot Study. <i>Tumor Biology</i> , 2006, 27, 104-114.	0.8	25
510	Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1487-1493.	3.2	60
511	Lost in (the Business of) Translation: Invest in the Youth. <i>Clinical Cancer Research</i> , 2006, 12, 669.2-669.	3.2	2
512	Human Kallikrein 6 Expression in Salivary Gland Tumors. <i>Journal of Histochemistry and Cytochemistry</i> , 2006, 54, 337-342.	1.3	20
513	Effect of Testosterone Administration on Serum and Urine Kallikrein Concentrations in Female-to-Male Transsexuals. <i>Clinical Chemistry</i> , 2006, 52, 1546-1551.	1.5	13
514	Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. <i>Biological Chemistry</i> , 2006, 387, 677-685.	1.2	71
515	The kallikrein world: an update on the human tissue kallikreins. <i>Biological Chemistry</i> , 2006, 387, 643-52.	1.2	60
516	Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. <i>Biological Chemistry</i> , 2006, 387, 807-811.	1.2	79
517	The role of human tissue kallikreins 7 and 8 in intracranial malignancies. <i>Biological Chemistry</i> , 2006, 387, 1607-1612.	1.2	29
518	Purification and Characterization of Human Kallikrein 11, a Candidate Prostate and Ovarian Cancer Biomarker, from Seminal Plasma. <i>Clinical Cancer Research</i> , 2006, 12, 742-750.	3.2	47
519	Unfavorable Prognostic Value of Human Kallikrein 7 Quantified by ELISA in Ovarian Cancer Cytosols. <i>Clinical Chemistry</i> , 2006, 52, 1879-1886.	1.5	44
520	The epigenetic basis for the aberrant expression of kallikreins in human cancers. <i>Biological Chemistry</i> , 2006, 387, 795-9.	1.2	30
521	A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. <i>Biological Chemistry</i> , 2006, 387, 637-41.	1.2	123
522	Cellular distribution of human tissue kallikreins: immunohistochemical localization. <i>Biological Chemistry</i> , 2006, 387, 653-63.	1.2	60

#	ARTICLE	IF	CITATIONS
523	Activation and enzymatic characterization of recombinant human kallikrein 8. <i>Biological Chemistry</i> , 2006, 387, 723-31.	1.2	26
524	Human tissue kallikrein 9: production of recombinant proteins and specific antibodies. <i>Biological Chemistry</i> , 2006, 387, 733-40.	1.2	16
525	Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). <i>Biological Chemistry</i> , 2006, 387, 817-24.	1.2	97
526	Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. <i>Biological Chemistry</i> , 2006, 387, 801-805.	1.2	20
527	Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals. <i>Journal of Histochemistry and Cytochemistry</i> , 2006, 54, 905-910.	1.3	70
528	Serum Proteomic Profiling by Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry for Cancer Diagnosis: Next Steps. <i>Cancer Research</i> , 2006, 66, 5540-5541.	0.4	67
529	Serum and Urine Tissue Kallikrein Concentrations in Male-to-Female Transsexuals Treated with Antiandrogens and Estrogens. <i>Clinical Chemistry</i> , 2006, 52, 1356-1365.	1.5	5
530	Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins. <i>Biological Chemistry</i> , 2006, 387, 749-759.	1.2	29
531	Proteinase-activated Receptors, Targets for Kallikrein Signaling*. <i>Journal of Biological Chemistry</i> , 2006, 281, 32095-32112.	1.6	217
532	Validation of Breast Cancer Biomarkers Identified by Mass Spectrometry. <i>Clinical Chemistry</i> , 2006, 52, 771-772.	1.5	16
533	Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. <i>British Journal of Cancer</i> , 2006, 94, 540-547.	2.9	23
534	B7-H4 Is a Novel Membrane-Bound Protein and a Candidate Serum and Tissue Biomarker for Ovarian Cancer. <i>Cancer Research</i> , 2006, 66, 1570-1575.	0.4	162
535	Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis. <i>Clinical Cancer Research</i> , 2006, 12, 89-96.	3.2	105
536	Human Tissue Kallikrein 5 Is a Member of a Proteolytic Cascade Pathway Involved in Seminal Clot Liquefaction and Potentially in Prostate Cancer Progression. <i>Journal of Biological Chemistry</i> , 2006, 281, 12743-12750.	1.6	94
537	Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. <i>BJU International</i> , 2005, 96, 521-527.	1.3	28
538	Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. <i>British Journal of Dermatology</i> , 2005, 153, 274-281.	1.4	130
539	Quantification of Human Tissue Kallikreins in the Stratum Corneum: Dependence on Age and Gender. <i>Journal of Investigative Dermatology</i> , 2005, 125, 1182-1189.	0.3	74
540	A survey of alternative transcripts of human tissue kallikrein genes. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2005, 1755, 1-14.	3.3	42

#	ARTICLE	IF	CITATIONS
541	Potential markers that complement expression of CA125 in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 99, 267-277.	0.6	324
542	Identification of New Splice Variants and Differential Expression of the Human Kallikrein 10 Gene, a Candidate Cancer Biomarker. <i>Tumor Biology</i> , 2005, 26, 227-235.	0.8	32
543	Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression. <i>Journal of Biological Chemistry</i> , 2005, 280, 14628-14635.	1.6	137
544	Intron Retention: A Common Splicing Event within the Human Kallikrein Gene Family. <i>Clinical Chemistry</i> , 2005, 51, 506-515.	1.5	56
545	Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3320-3325.	3.2	52
546	Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. <i>Biological Chemistry</i> , 2005, 386, 291-298.	1.2	52
547	Downregulation of Human Kallikrein 10 (KLK10/NES1) by CpG Island Hypermethylation in Breast, Ovarian and Prostate Cancers. <i>Tumor Biology</i> , 2005, 26, 324-336.	0.8	59
548	Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications. <i>Advances in Clinical Chemistry</i> , 2005, 39, 11-79.	1.8	58
549	Human Kallikrein 4: Quantitative Study in Tissues and Evidence for Its Secretion into Biological Fluids. <i>Clinical Chemistry</i> , 2005, 51, 1432-1442.	1.5	59
550	Human tissue kallikrein gene family: applications in cancer. <i>Cancer Letters</i> , 2005, 224, 1-22.	3.2	128
551	Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. <i>Clinical Cancer Research</i> , 2005, 11, 963-5.	3.2	69
552	Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. <i>Thrombosis and Haemostasis</i> , 2004, 91, 180-186.	1.8	65
553	The Kallikrein Gene 5 Splice Variant 2 Is a New Biomarker for Breast and Ovarian Cancer. <i>Tumor Biology</i> , 2004, 25, 221-227.	0.8	15
554	Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker. <i>Journal of Clinical Oncology</i> , 2004, 22, 678-685.	0.8	73
555	Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker for Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 5293-5294.	3.2	16
556	How Are We Going to Discover New Cancer Biomarkers? A Proteomic Approach for Bladder Cancer. <i>Clinical Chemistry</i> , 2004, 50, 793-795.	1.5	32
557	Differential Expression of a Human Kallikrein 5 (KLK5) Splice Variant in Ovarian and Prostate Cancer. <i>Tumor Biology</i> , 2004, 25, 149-156.	0.8	23
558	Molecular Cloning of a New Gene Which Is Differentially Expressed in Breast and Prostate Cancers. <i>Tumor Biology</i> , 2004, 25, 122-133.	0.8	11

#	ARTICLE	IF	CITATIONS
559	Human Kallikrein 6 Degrades Extracellular Matrix Proteins and May Enhance the Metastatic Potential of Tumour Cells. <i>Tumor Biology</i> , 2004, 25, 193-199.	0.8	97
560	Kallikrein gene downregulation in breast cancer. <i>British Journal of Cancer</i> , 2004, 90, 167-172.	2.9	80
561	Assessment of serum prostate specific antigen in childhood. <i>BJU International</i> , 2004, 93, 838-840.	1.3	7
562	The emerging roles of human tissue kallikreins in cancer. <i>Nature Reviews Cancer</i> , 2004, 4, 876-890.	12.8	595
563	Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer. <i>Cancer Detection and Prevention</i> , 2004, 28, 27-31.	2.1	36
564	Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. <i>Clinical Biochemistry</i> , 2004, 37, 230-237.	0.8	43
565	An update on human and mouse glandular kallikreins. <i>Clinical Biochemistry</i> , 2004, 37, 258-260.	0.8	32
566	Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. <i>Clinical Biochemistry</i> , 2004, 37, 823-829.	0.8	47
567	Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. <i>International Journal of Cancer</i> , 2004, 108, 588-591.	2.3	36
568	Recent Advances in Cancer Biomarkers. <i>Clinical Biochemistry</i> , 2004, 37, 503-504.	0.8	5
569	Cloning of a kallikrein pseudogene. <i>Clinical Biochemistry</i> , 2004, 37, 961-967.	0.8	19
570	Sequence and evolutionary analysis of the human trypsin subfamily of serine peptidases. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2004, 1698, 77-86.	1.1	39
571	Proteomic patterns to identify ovarian cancer: 3 years on. <i>Expert Review of Molecular Diagnostics</i> , 2004, 4, 575-577.	1.5	31
572	In silico Analysis of the Human Kallikrein Gene 6. <i>Tumor Biology</i> , 2004, 25, 282-289.	0.8	35
573	Analysis of Serum Proteomic Patterns for Early Cancer Diagnosis: Drawing Attention to Potential Problems. <i>Journal of the National Cancer Institute</i> , 2004, 96, 353-356.	3.0	393
574	Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool. <i>Molecular and Cellular Proteomics</i> , 2004, 3, 367-378.	2.5	568
575	Hepsin is Highly Over Expressed in and a New Candidate for a Prognostic Indicator in Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, 187-191.	0.2	117
576	Re: Diagnostic Potential of Serum Proteomic Patterns in Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, 1244-1245.	0.2	12

#	ARTICLE	IF	CITATIONS
577	Development of an Immunofluorometric Assay and Quantification of Human Kallikrein 7 in Tissue Extracts and Biological Fluids. <i>Clinical Chemistry</i> , 2004, 50, 709-716.	1.5	44
578	Complex formation between human kallikrein 13 and serum protease inhibitors. <i>Clinica Chimica Acta</i> , 2004, 339, 157-167.	0.5	26
579	Cloning and characterization of novel isoforms of the human kallikrein 6 gene. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 54-61.	1.0	35
580	Human kallikrein 13 involvement in extracellular matrix degradation. <i>Biochemical and Biophysical Research Communications</i> , 2004, 323, 1084-1090.	1.0	57
581	In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. <i>Anticancer Research</i> , 2004, 24, 43-51.	0.5	53
582	Human tissue kallikreins: physiologic roles and applications in cancer. <i>Molecular Cancer Research</i> , 2004, 2, 257-80.	1.5	83
583	Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer. <i>Molecular Cancer Research</i> , 2004, 2, 257-280.	1.5	293
584	The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 149-158.	1.1	46
585	The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2003, 1628, 88-96.	2.4	28
586	Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. <i>International Journal of Cancer</i> , 2003, 106, 605-610.	2.3	56
587	Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. <i>Clinical Biochemistry</i> , 2003, 36, 135-143.	0.8	68
588	An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. <i>Clinical Biochemistry</i> , 2003, 36, 443-452.	0.8	89
589	Human tissue kallikreins and testicular cancer. <i>Apmis</i> , 2003, 111, 225-233.	0.9	38
590	Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. <i>Prostate</i> , 2003, 54, 220-229.	1.2	40
591	Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. <i>Prostate</i> , 2003, 56, 287-292.	1.2	59
592	Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. <i>Prostate Cancer and Prostatic Diseases</i> , 2003, 6, 223-227.	2.0	37
593	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. <i>Journal of Urology</i> , 2003, 169, 361-364.	0.2	53
594	Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. <i>Clinica Chimica Acta</i> , 2003, 337, 115-126.	0.5	30

#	ARTICLE	IF	CITATIONS
595	Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics?. <i>Clinical Chemistry</i> , 2003, 49, 1272-1275.	1.5	322
596	Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. <i>Urology</i> , 2003, 61, 1042-1046.	0.5	41
597	Genomic overview of serine proteases. <i>Biochemical and Biophysical Research Communications</i> , 2003, 305, 28-36.	1.0	52
598	Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 948-955.	1.0	134
599	Role of kallikrein enzymes in the central nervous system. <i>Clinica Chimica Acta</i> , 2003, 329, 1-8.	0.5	75
600	Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. <i>Gene</i> , 2003, 310, 79-89.	1.0	22
601	Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 84, 493-502.	1.2	15
602	Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection. <i>Journal of Clinical Oncology</i> , 2003, 21, 2312-2319.	0.8	36
603	Human Kallikrein 13 Expression in Normal Tissues: An Immunohistochemical Study. <i>Journal of Histochemistry and Cytochemistry</i> , 2003, 51, 493-501.	1.3	38
604	Human Kallikrein 8: Immunoassay Development and Identification in Tissue Extracts and Biological Fluids. <i>Clinical Chemistry</i> , 2003, 49, 87-96.	1.5	55
605	Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 1035-1043.	0.8	188
606	Human Kallikrein 13: Production and Purification of Recombinant Protein and Monoclonal and Polyclonal Antibodies, and Development of a Sensitive and Specific Immunofluorometric Assay. <i>Clinical Chemistry</i> , 2003, 49, 77-86.	1.5	62
607	Purification of Human Kallikrein 6 from Biological Fluids and Identification of its Complex with $\hat{\pm}$ 1-Antichymotrypsin. <i>Clinical Chemistry</i> , 2003, 49, 746-751.	1.5	26
608	Steroid Hormone Regulation and Prognostic Value of the Human Kallikrein Gene 14 in Ovarian Cancer. <i>American Journal of Clinical Pathology</i> , 2003, 119, 346-355.	0.4	62
609	Prognostic Value of the Human Kallikrein Gene 15 Expression in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 3119-3126.	0.8	69
610	Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. <i>British Journal of Cancer</i> , 2003, 88, 1101-1104.	2.9	84
611	Re: Serum Proteomic Patterns for Detection of Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 489-489.	3.0	40
612	Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis. <i>Tumor Biology</i> , 2003, 24, 299-309.	0.8	45

#	ARTICLE	IF	CITATIONS
613	Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. <i>Thrombosis and Haemostasis</i> , 2003, 89, 1081-1088.	1.8	37
614	Tissue kallikreins: new players in normal and abnormal cell growth?. <i>Thrombosis and Haemostasis</i> , 2003, 90, 7-16.	1.8	30
615	Human Kallikreins: Common Structural Features, Sequence Analysis and Evolution. <i>Current Genomics</i> , 2003, 4, 147-165.	0.7	30
616	Emerging Interest in the Kallikrein Gene Family for Understanding and Diagnosing Cancer. <i>Oncology Research</i> , 2003, 13, 381-391.	0.6	43
617	Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue. <i>Journal of Urology</i> , 2003, , 361-364.	0.2	2
618	Steroid Hormone Regulation and Prognostic Value of the Human Kallikrein Gene 14 in Ovarian Cancer. <i>American Journal of Clinical Pathology</i> , 2003, 119, 0-0.	0.4	0
619	The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. <i>Cancer Research</i> , 2003, 63, 807-11.	0.4	123
620	Parallel overexpression of seven kallikrein genes in ovarian cancer. <i>Cancer Research</i> , 2003, 63, 2223-7.	0.4	126
621	Human kallikrein 8, a novel biomarker for ovarian carcinoma. <i>Cancer Research</i> , 2003, 63, 2771-4.	0.4	71
622	Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. <i>Cancer Research</i> , 2003, 63, 3958-65.	0.4	109
623	Tissue kallikreins: new players in normal and abnormal cell growth?. <i>Thrombosis and Haemostasis</i> , 2003, 90, 7-16.	1.8	12
624	The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. <i>Cancer Research</i> , 2003, 63, 6543-6.	0.4	42
625	Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. <i>Cancer Research</i> , 2003, 63, 9032-41.	0.4	92
626	Quantitative analysis of kallikrein 15 gene expression in prostate tissue. <i>Journal of Urology</i> , 2003, 169, 361-4.	0.2	18
627	Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. <i>British Journal of Cancer</i> , 2002, 87, 339-343.	2.9	67
628	Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. <i>British Journal of Cancer</i> , 2002, 87, 1287-1293.	2.9	40
629	Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. <i>British Journal of Cancer</i> , 2002, 86, 1457-1464.	2.9	58
630	The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. <i>British Journal of Cancer</i> , 2002, 87, 1294-1300.	2.9	42

#	ARTICLE	IF	CITATIONS
631	Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. <i>British Journal of Cancer</i> , 2002, 87, 763-771.	2.9	71
632	Human Tissue Kallikreins: A New Enzymatic Cascade Pathway?. <i>Biological Chemistry</i> , 2002, 383, 1045-57.	1.2	89
633	Expression Profiling in Squamous Carcinoma Cells Reveals Pleiotropic Effects of Vitamin D3 Analog EB1089 Signaling on Cell Proliferation, Differentiation, and Immune System Regulation. <i>Molecular Endocrinology</i> , 2002, 16, 1243-1256.	3.7	173
634	Familial Aggregation of Diabetes and Hypertension in a Case-Control Study of Colorectal Neoplasia. <i>American Journal of Epidemiology</i> , 2002, 156, 702-713.	1.6	27
635	Human Kallikrein 10 Expression in Normal Tissues by Immunohistochemistry. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 1247-1261.	1.3	42
636	Expanded Human Tissue Kallikrein Family – A Novel Panel of Cancer Biomarkers. <i>Tumor Biology</i> , 2002, 23, 185-192.	0.8	82
637	Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. <i>Urology</i> , 2002, 59, 2-8.	0.5	72
638	Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. <i>Urology</i> , 2002, 60, 714-718.	0.5	49
639	Flavonoids can block PSA production by breast and prostate cancer cell lines. <i>Clinica Chimica Acta</i> , 2002, 317, 17-26.	0.5	47
640	Duties and responsibilities of laboratory scientists. <i>Clinica Chimica Acta</i> , 2002, 319, 111-115.	0.5	3
641	Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new siglec pseudogenes. <i>Gene</i> , 2002, 286, 259-270.	1.0	28
642	Cloning, physical mapping and structural characterization of the human $\hat{\pm}$ A -adaptin gene. <i>Gene</i> , 2002, 289, 191-199.	1.0	8
643	Cancer Diagnostics: Discovery and Clinical Applications"Introduction. <i>Clinical Chemistry</i> , 2002, 48, 1145-1146.	1.5	6
644	Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer. <i>Clinical Chemistry</i> , 2002, 48, 1241-1250.	1.5	82
645	Multicenter Evaluation of an Artificial Neural Network to Increase the Prostate Cancer Detection Rate and Reduce Unnecessary Biopsies. <i>Clinical Chemistry</i> , 2002, 48, 1279-1287.	1.5	126
646	Human Tissue Kallikreins: A Family of New Cancer Biomarkers. <i>Clinical Chemistry</i> , 2002, 48, 1198-1205.	1.5	218
647	Detection of Human Kallikrein 4 in Healthy and Cancerous Prostatic Tissues by Immunofluorometry and Immunohistochemistry. <i>Clinical Chemistry</i> , 2002, 48, 1232-1240.	1.5	67
648	Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer.. <i>Environmental Health Perspectives</i> , 2002, 110, 241-246.	2.8	57

#	ARTICLE	IF	CITATIONS
649	Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer. <i>Cancer Detection and Prevention</i> , 2002, 26, 149-157.	2.1	32
650	Cockayne syndrome in three sisters with varying clinical presentation. <i>American Journal of Medical Genetics Part A</i> , 2002, 111, 81-85.	2.4	21
651	Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. <i>International Journal of Cancer</i> , 2002, 100, 507-514.	2.3	43
652	Ethnic variation in kallikrein expression in nipple aspirate fluid. <i>International Journal of Cancer</i> , 2002, 100, 678-682.	2.3	13
653	Flavonoids and steroid hormone-dependent cancers. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 777, 219-232.	1.2	60
654	Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. <i>Prostate</i> , 2002, 51, 126-132.	1.2	64
655	Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. <i>Prostate</i> , 2002, 51, 35-41.	1.2	40
656	Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. <i>British Journal of Cancer</i> , 2002, 86, 1790-1796.	2.9	51
657	A comparison of the anticarcinogenic properties of four red wine polyphenols. <i>Clinical Biochemistry</i> , 2002, 35, 119-124.	0.8	199
658	Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. <i>Clinical Biochemistry</i> , 2002, 35, 225-231.	0.8	49
659	Immunohistochemical localization of human kallikreins 6 and 10 in pancreatic islets. <i>The Histochemical Journal</i> , 2002, 34, 313-322.	0.6	17
660	Expression Profiling in Squamous Carcinoma Cells Reveals Pleiotropic Effects of Vitamin D3 Analog EB1089 Signaling on Cell Proliferation, Differentiation, and Immune System Regulation. <i>Molecular Endocrinology</i> , 2002, 16, 1243-1256.	3.7	52
661	The Science of Man in Ancient Greece. Maria Michela Sassi. Chicago and London: The University of Chicago Press, 2001, 254 pp., \$34.00, hardcover. ISBN 0-226-73530-3.. <i>Clinical Chemistry</i> , 2002, 48, 396-396.	1.5	0
662	Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. <i>Cancer Research</i> , 2002, 62, 295-300.	0.4	137
663	Human tissue kallikreins: a family of new cancer biomarkers. <i>Clinical Chemistry</i> , 2002, 48, 1198-205.	1.5	74
664	Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. <i>Clinical Chemistry</i> , 2002, 48, 1232-40.	1.5	17
665	Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. <i>Clinical Chemistry</i> , 2002, 48, 1241-50.	1.5	33
666	Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. <i>Clinical Chemistry</i> , 2002, 48, 1279-87.	1.5	44

#	ARTICLE	IF	CITATIONS
667	Absorption of trans-resveratrol in rats. <i>Methods in Enzymology</i> , 2001, 335, 145-154.	0.4	105
668	Molecular Cloning of a Novel Human Gene on Chromosome 4p11 by Immunoscreening of an Ovarian Carcinoma cDNA Library. <i>Biochemical and Biophysical Research Communications</i> , 2001, 280, 401-406.	1.0	20
669	Cloning and Molecular Characterization of Two Splice Variants of a New Putative Member of the Siglec-3-like Subgroup of Siglecs. <i>Biochemical and Biophysical Research Communications</i> , 2001, 284, 887-899.	1.0	13
670	Molecular Characterization, Tissue Expression, and Mapping of a Novel Siglec-like Gene (SLG2) with Three Splice Variants. <i>Biochemical and Biophysical Research Communications</i> , 2001, 284, 900-910.	1.0	17
671	Identification and Characterization of a Novel Human Testis-Specific Kinase Substrate Gene Which Is Downregulated in Testicular Tumors. <i>Biochemical and Biophysical Research Communications</i> , 2001, 285, 400-408.	1.0	14
672	Sequence Analysis of the Human Kallikrein Gene Locus Identifies a Unique Polymorphic Minisatellite Element. <i>Biochemical and Biophysical Research Communications</i> , 2001, 285, 1321-1329.	1.0	13
673	Molecular Cloning, Physical Mapping, and Expression Analysis of a Novel Gene, BCL2L12, Encoding a Proline-Rich Protein with a Highly Conserved BH2 Domain of the Bcl-2 Family. <i>Genomics</i> , 2001, 72, 217-221.	1.3	89
674	Molecular Cloning of a Novel Human Acid Phosphatase Gene (ACPT) That Is Highly Expressed in the Testis. <i>Genomics</i> , 2001, 74, 385-395.	1.3	53
675	Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. <i>Urology</i> , 2001, 57, 471-475.	0.5	34
676	Human kallikrein 10: a novel tumor marker for ovarian carcinoma?. <i>Clinica Chimica Acta</i> , 2001, 306, 111-118.	0.5	94
677	Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. <i>Clinica Chimica Acta</i> , 2001, 312, 213-219.	0.5	23
678	The Role of Molecular Forms of Prostate-Specific Antigen (PSA or hK3) and of Human Glandular Kallikrein 2 (hK2) in the Diagnosis and Monitoring of Prostate Cancer and in Extra-Prostatic Disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2001, 38, 357-399.	2.7	26
679	Human tissue kallikrein gene family: a rich source of novel disease biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2001, 1, 182-190.	1.5	54
680	Immunofluorometric Assay of Human Kallikrein 10 and Its Identification in Biological Fluids and Tissues. <i>Clinical Chemistry</i> , 2001, 47, 237-246.	1.5	78
681	Signal Amplification in Time-resolved Fluorometry. <i>Clinical Chemistry</i> , 2001, 47, 380-381.	1.5	4
682	Prostate-Specific Antigen Levels in Nipple Aspirate Fluid. <i>Journal of Clinical Oncology</i> , 2001, 19, 3160-3160.	0.8	8
683	Prostaglandin D Synthase Does Not Produce Prostate-specific Antigen Cross-Reactivity in Renal Cell Carcinoma. <i>Clinical Chemistry</i> , 2001, 47, 607-608.	1.5	1
684	Expression of the kallikrein gene family in normal and Alzheimer's disease brain. <i>NeuroReport</i> , 2001, 12, 2747-2751.	0.6	56

#	ARTICLE	IF	CITATIONS
685	Do wine polyphenols modulate p53 gene expression in human cancer cell lines?. <i>Clinical Biochemistry</i> , 2001, 34, 415-420.	0.8	48
686	The World of Resveratrol. <i>Advances in Experimental Medicine and Biology</i> , 2001, 492, 159-182.	0.8	80
687	Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. <i>British Journal of Cancer</i> , 2001, 84, 643-650.	2.9	116
688	Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer. <i>British Journal of Cancer</i> , 2001, 84, 760-767.	2.9	16
689	Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. <i>British Journal of Cancer</i> , 2001, 85, 220-224.	2.9	70
690	Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer. <i>British Journal of Cancer</i> , 2001, 85, 393-397.	2.9	29
691	Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer. <i>British Journal of Cancer</i> , 2001, 85, 190-198.	2.9	21
692	Molecular Cloning of the Human Kallikrein 15 Gene (KLK15). <i>Journal of Biological Chemistry</i> , 2001, 276, 53-61.	1.6	103
693	The Spectrum of Human Kallikrein 6 (Zyme/Protease M/Neurosin) Expression in Human Tissues as Assessed by Immunohistochemistry. <i>Journal of Histochemistry and Cytochemistry</i> , 2001, 49, 1431-1441.	1.3	80
694	The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease*. <i>Endocrine Reviews</i> , 2001, 22, 184-204.	8.9	520
695	Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1558-1561.	1.8	31
696	Preliminary examination of time-resolved fluorometry for protein array applications. <i>Luminescence</i> , 2000, 15, 409-413.	1.5	23
697	Identification of exon 1 of prostate/KLK-L1 gene. <i>Clinical Biochemistry</i> , 2000, 33, 221-222.	0.8	4
698	Polyvinylamine-streptavidin complexes labeled with a europium chelator: a universal detection reagent for solid-phase time resolved fluorometric applications. <i>Clinical Biochemistry</i> , 2000, 33, 345-350.	0.8	32
699	Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. <i>Clinical Biochemistry</i> , 2000, 33, 369-375.	0.8	114
700	An alternatively spliced variant of KLK4 expressed in prostatic tissue. <i>Clinical Biochemistry</i> , 2000, 33, 599-600.	0.8	12
701	Human Kallikrein 6 as a Biomarker of Alzheimer's Disease. <i>Clinical Biochemistry</i> , 2000, 33, 663-667.	0.8	103
702	p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. <i>Clinical Biochemistry</i> , 2000, 33, 53-62.	0.8	29

#	ARTICLE	IF	CITATIONS
703	Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. <i>Clinical Biochemistry</i> , 2000, 33, 115-123.	0.8	27
704	Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. <i>Clinical Biochemistry</i> , 2000, 33, 579-583.	0.8	147
705	Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis?. <i>Digestive Diseases and Sciences</i> , 2000, 45, 2018-2021.	1.1	22
706	Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 263-270.	1.1	54
707	Is ICI 182,780 an antiprogesterin in addition to being an antiestrogen?. <i>Breast Cancer Research and Treatment</i> , 2000, 60, 1-8.	1.1	4
708	Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 153-161.	1.1	77
709	The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 1-14.	1.1	94
710	Steroid hormone activity of flavonoids and related compounds. <i>Breast Cancer Research and Treatment</i> , 2000, 62, 35-49.	1.1	187
711	Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. <i>Breast Cancer Research and Treatment</i> , 2000, 61, 111-119.	1.1	18
712	Serum and Urinary Prostate-specific Antigen and Urinary Human Glandular Kallikrein Concentrations Are Significantly Increased after Testosterone Administration in Female-to-Male Transsexuals. <i>Clinical Chemistry</i> , 2000, 46, 859-862.	1.5	27
713	Genistein: A Potent Natural Antiandrogen. <i>Clinical Chemistry</i> , 2000, 46, 887-888.	1.5	20
714	Prostate-specific Antigen: A Cancer Fighter and a Valuable Messenger?. <i>Clinical Chemistry</i> , 2000, 46, 896-900.	1.5	70
715	Identification and Characterization of KLK-L4, a New Kallikrein-like Gene That Appears to be Down-regulated in Breast Cancer Tissues. <i>Journal of Biological Chemistry</i> , 2000, 275, 11891-11898.	1.6	78
716	Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen. <i>Journal of Clinical Oncology</i> , 2000, 18, 1036-1036.	0.8	99
717	New Nomenclature for the Human Tissue Kallikrein Gene Family. <i>Clinical Chemistry</i> , 2000, 46, 1855-1858.	1.5	163
718	Elevated Serum Prostate-Specific Antigen Levels in a Woman with Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2000, 343, 890-891.	13.9	24
719	Genomic Organization of the Human Kallikrein Gene Family on Chromosome 19q13.3â€“q13.4. <i>Biochemical and Biophysical Research Communications</i> , 2000, 276, 125-133.	1.0	183
720	Genomic Organization, Physical Mapping, and Expression Analysis of the Human Protein Arginine Methyltransferase 1 Gene. <i>Biochemical and Biophysical Research Communications</i> , 2000, 278, 349-359.	1.0	65

#	ARTICLE	IF	CITATIONS
721	Molecular Characterization of a Siglec8 Variant Containing Cytoplasmic Tyrosine-Based Motifs, and Mapping of the Siglec8 Gene. <i>Biochemical and Biophysical Research Communications</i> , 2000, 278, 775-781.	1.0	37
722	Genomic Organization, Mapping, Tissue Expression, and Hormonal Regulation of Trypsin-like Serine Protease (TLSP PRSS20), a New Member of the Human Kallikrein Gene Family. <i>Genomics</i> , 2000, 63, 88-96.	1.3	62
723	The Expanded Human Kallikrein Gene Family: Locus Characterization and Molecular Cloning of a New Member, KLK-L3 (KLK9). <i>Genomics</i> , 2000, 65, 184-194.	1.3	68
724	Identification and Molecular Characterization of a Novel Member of the Siglec Family (SIGLEC9). <i>Genomics</i> , 2000, 67, 171-178.	1.3	32
725	KLK12 Is a Novel Serine Protease and a New Member of the Human Kallikrein Gene Family—Differential Expression in Breast Cancer. <i>Genomics</i> , 2000, 69, 331-341.	1.3	84
726	The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family—genomic characterization, mapping, tissue expression and hormonal regulation. <i>Gene</i> , 2000, 254, 119-128.	1.0	87
727	The New Human Kallikrein Gene Family: Implications in Carcinogenesis. <i>Trends in Endocrinology and Metabolism</i> , 2000, 11, 54-60.	3.1	240
728	Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity—A controlled crossover trial. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 537-543.	1.5	81
729	Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. <i>Clinica Chimica Acta</i> , 2000, 300, 171-180.	0.5	18
730	Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. <i>Clinica Chimica Acta</i> , 2000, 292, 127-138.	0.5	13
731	Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. <i>Urology</i> , 2000, 56, 527-532.	0.5	99
732	DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSEXUALS. <i>Journal of Urology</i> , 2000, 163, 802-805.	0.2	15
733	Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. <i>American Journal of Clinical Nutrition</i> , 1999, 69, 395-402.	2.2	186
734	Human Glandular Kallikrein in Breast Milk, Amniotic Fluid, and Breast Cyst Fluid. <i>Clinical Chemistry</i> , 1999, 45, 1774-1780.	1.5	34
735	Characterization of Monoclonal Antibodies for Prostate-specific Antigen and Development of Highly Sensitive Free Prostate-specific Antigen Assays. <i>Clinical Chemistry</i> , 1999, 45, 347-354.	1.5	30
736	The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA. <i>Clinical Chemistry</i> , 1999, 45, 1960-1966.	1.5	103
737	Development of an Ultrasensitive Immunoassay for Human Glandular Kallikrein with No Cross-Reactivity from Prostate-specific Antigen. <i>Clinical Chemistry</i> , 1999, 45, 790-799.	1.5	56
738	Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. <i>British Journal of Cancer</i> , 1999, 79, 888-894.	2.9	40

#	ARTICLE	IF	CITATIONS
739	Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. <i>British Journal of Cancer</i> , 1999, 81, 490-495.	2.9	12
740	Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification. <i>Clinical Biochemistry</i> , 1999, 32, 39-44.	0.8	6
741	Rapid and accurate determination of (CAG) _n repeats in the androgen receptor gene using polymerase chain reaction and automated fragment analysis. <i>Clinical Biochemistry</i> , 1999, 32, 327-332.	0.8	28
742	Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. <i>Cancer</i> , 1999, 85, 891-898.	2.0	29
743	Amplification of human genomic DNA sequences with polymerase chain reaction using a single oligonucleotide primer. <i>Journal of Clinical Laboratory Analysis</i> , 1999, 13, 69-74.	0.9	1
744	Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. <i>Journal of Clinical Laboratory Analysis</i> , 1999, 13, 75-81.	0.9	18
745	Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2. <i>Journal of Clinical Laboratory Analysis</i> , 1999, 13, 241-245.	0.9	4
746	Seminal plasma biochemical markers and their association with semen analysis findings. <i>Urology</i> , 1999, 53, 596-603.	0.5	59
747	Characterization of the BRCA1-like immunoreactivity of human seminal plasma. <i>Urology</i> , 1999, 54, 753-762.	0.5	1
748	Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. <i>Urology</i> , 1999, 53, 32-37.	0.5	83
749	Molecular Characterization of Zyme/Protease M/Neurosin (PRSS9), A Hormonally Regulated Kallikrein-like Serine Protease. <i>Genomics</i> , 1999, 62, 251-259.	1.3	94
750	The New Kallikrein-like Gene, KLK-L2. <i>Journal of Biological Chemistry</i> , 1999, 274, 37511-37516.	1.6	83
751	Prostate Specific Antigen Production by Breast Tumors After Induction with Oral Contraceptives. <i>Clinical Biochemistry</i> , 1998, 31, 285-288.	0.8	7
752	Fragment analysis of the p53 gene in ovarian tumors. <i>Clinical Biochemistry</i> , 1998, 31, 551-553.	0.8	1
753	A candidate new gene on human chromosome 5q12 contains a motif that is found in transcriptional co-activators. <i>Clinical Biochemistry</i> , 1998, 31, 687-688.	0.8	0
754	Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice. <i>Breast Cancer Research and Treatment</i> , 1998, 48, 73-80.	1.1	5
755	Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. , 1998, 79, 147-152.		10
756	Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. , 1998, 79, 494-501.		11

#	ARTICLE	IF	CITATIONS
757	Insulin-like growth factor-binding protein-3 and breast cancer survival. , 1998, 79, 624-628.		51
758	Changes in serum carbohydrate-deficient transferrin and gammaglutamyl transferase after moderate wine consumption in healthy males. , 1998, 12, 92-97.		16
759	Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis: Application to breast and ovarian tumors. , 1998, 12, 250-256.		7
760	Prostate-specific Antigen: Its Usefulness in Clinical Medicine. Trends in Endocrinology and Metabolism, 1998, 9, 310-316.	3.1	133
761	New 11 β -aryl-substituted steroids exhibit both progestational and antiprogestational activity. Steroids, 1998, 63, 523-530.	0.8	20
762	Induction of Prostate-Specific Antigen Expression by Synthetic Progestins in Patients With Prostate and Breast Cancer. Mayo Clinic Proceedings, 1998, 73, 706-707.	1.4	3
763	Structural Characterization and Mapping of the Normal Epithelial Cell-Specific 1 Gene. Biochemical and Biophysical Research Communications, 1998, 247, 580-586.	1.0	48
764	Modulation of Androgen and Progesterone Receptors by Phytochemicals in Breast Cancer Cell Lines. Biochemical and Biophysical Research Communications, 1998, 248, 935-939.	1.0	38
765	Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features*. Endocrine Reviews, 1998, 19, 365-396.	8.9	154
766	Prostate-Specific Antigen or Human Kallikrein 3?. Tumor Biology, 1998, 19, 65-68.	0.8	7
767	Rapid sequencing of the p53 gene with a new automated DNA sequencer. Clinical Chemistry, 1998, 44, 1397-1403.	1.5	17
768	Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. Clinical Chemistry, 1998, 44, 205-208.	1.5	13
769	Is Prostate-Specific Antigen Present in Female Serum?. Clinical Chemistry, 1998, 44, 691-692.	1.5	17
770	Exon 5 of the p53 gene is a target for deletions in ovarian cancer. Clinical Chemistry, 1998, 44, 72-77.	1.5	8
771	Insulin-like growth factor-binding protein-3 and breast cancer survival. International Journal of Cancer, 1998, 79, 624-628.	2.3	2
772	Clinical Application of Ultrasensitive Prostate-Specific Antigen Assays. Journal of the National Cancer Institute, 1997, 89, 1077-1077.	3.0	2
773	Frequency of Expression of Prostate-Specific Antigen mRNA in Lung Tumors. American Journal of Clinical Pathology, 1997, 108, 184-190.	0.4	24
774	Comparison of Immunofluorometry and Immunohistochemistry for the Detection of p53 Protein in Lung Cancer Specimens. American Journal of Clinical Pathology, 1997, 107, 308-316.	0.4	7

#	ARTICLE	IF	CITATIONS
775	Relative Contributions of Polyphenolic Constituents to the Antioxidant Status of Wines:Â Development of a Predictive Model. <i>Journal of Agricultural and Food Chemistry</i> , 1997, 45, 3995-4003.	2.4	66
776	Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. <i>Journal of Urology</i> , 1997, 157, 913-918.	0.2	58
777	NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN. <i>Urologic Clinics of North America</i> , 1997, 24, 275-282.	0.8	138
778	Prostate-Specific Antigen in Female Serum, a Potential New Marker of Androgen Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 777-780.	1.8	66
779	Clinical applications of tumor suppressor genes and oncogenes in cancer. <i>Clinica Chimica Acta</i> , 1997, 257, 157-180.	0.5	9
780	Prostate-specific antigen in serum during the menstrual cycle. <i>Clinical Chemistry</i> , 1997, 43, 1862-1867.	1.5	47
781	Prostate-Specific Antigen in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 1997, 43, 855-855.	1.5	29
782	Immunofluorometric assay of pepsinogen C and preliminary clinical applications. <i>Clinical Chemistry</i> , 1997, 43, 1365-1371.	1.5	17
783	Prostaglandin D Synthase Concentration in Cerebrospinal Fluid and Serum of Patients with Neurological Disorders. <i>Prostaglandins</i> , 1997, 54, 463-474.	1.2	55
784	A Multiresidue Derivatization Gas Chromatographic Assay for Fifteen Phenolic Constituents with Mass Selective Detection. <i>Analytical Chemistry</i> , 1997, 69, 4405-4409.	3.2	83
785	Wine as a biological fluid: History, production, and role in disease prevention. <i>Journal of Clinical Laboratory Analysis</i> , 1997, 11, 287-313.	0.9	568
786	Humoral immune response against p53 protein in patients with colorectal carcinoma. , 1997, 70, 46-51.		53
787	Resveratrol: A molecule whose time has come? And gone?. <i>Clinical Biochemistry</i> , 1997, 30, 91-113.	0.8	751
788	BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma. <i>Clinical Biochemistry</i> , 1997, 30, 425-432.	0.8	6
789	Wine as a biological fluid: History, production, and role in disease prevention. <i>Journal of Clinical Laboratory Analysis</i> , 1997, 11, 287-313.	0.9	11
790	The Periurethral Glands do not Significantly Influence the Serum Prostate Specific Antigen Concentration. <i>Journal of Urology</i> , 1996, 155, 1658-1660.	0.2	38
791	Re: The Clinical Usefulness of Prostate Specific Antigen: Update 1994. <i>Journal of Urology</i> , 1996, 155, 294-294.	0.2	1
792	Wine: does the colour count?. <i>Clinica Chimica Acta</i> , 1996, 246, 183-193.	0.5	48

#	ARTICLE	IF	CITATIONS
793	Wines and grape juices as modulators of platelet aggregation in healthy human subjects. <i>Clinica Chimica Acta</i> , 1996, 246, 163-182.	0.5	286
794	Method To Assay the Concentrations of Phenolic Constituents of Biological Interest in Wines. <i>Analytical Chemistry</i> , 1996, 68, 1688-1694.	3.2	224
795	Salivary Duct Carcinoma Secreting Prostate-Specific Antigen. <i>American Journal of Clinical Pathology</i> , 1996, 106, 242-247.	0.4	60
796	Prostaglandin D2 synthase in amniotic fluid and maternal serum: Possible association with fetal abnormalities. <i>Prostaglandins</i> , 1996, 51, 297.	1.2	0
797	Prostate specific antigen "a new constituent of breast cyst fluid. <i>Breast Cancer Research and Treatment</i> , 1996, 38, 259-264.	1.1	41
798	Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 171-178.	1.1	92
799	Does prostate cancer start at puberty?. , 1996, 10, 468-469.		20
800	Circulating antibodies against p53 protein in patients with ovarian carcinoma. , 1996, 78, 2146-2152.		53
801	Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. <i>Clinical Biochemistry</i> , 1996, 29, 193-200.	0.8	30
802	Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. <i>Clinical Biochemistry</i> , 1996, 29, 555-562.	0.8	31
803	DEVELOPMENT OF IN-HOUSE IMMUNOASSAYS. , 1996, , 555-568.		20
804	Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. <i>Clinical Biochemistry</i> , 1995, 28, 243-253.	0.8	19
805	Prostate-Specific antigen expression by various tumors. <i>Journal of Clinical Laboratory Analysis</i> , 1995, 9, 123-128.	0.9	112
806	Immunoreactive prostate-specific antigen in lung tumors. <i>Journal of Clinical Laboratory Analysis</i> , 1995, 9, 375-379.	0.9	30
807	Time-resolved detection of lanthanide luminescence for ultrasensitive bioanalytical assays. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 1995, 27, 3-19.	1.7	169
808	Assay of resveratrol glucosides and isomers in wine by direct-injection high-performance liquid chromatography. <i>Journal of Chromatography A</i> , 1995, 708, 89-98.	1.8	119
809	Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. , 1995, 66, 207-235.		132
810	Oral Contraceptive-induced Expression of Prostate-specific Antigen in the Female Breast. <i>Journal of Biological Chemistry</i> , 1995, 270, 6615-6618.	1.6	78

#	ARTICLE	IF	CITATIONS
811	Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. <i>Cancer</i> , 1995, 75, 1327-1338.	2.0	119
812	New diagnostic applications and physiological functions of prostate specific antigen. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1995, 55, 105-112.	0.6	28
813	Direct Gas Chromatographic-Mass Spectrometric Method To Assay cis-Resveratrol in Wines: Preliminary Survey of Its Concentration in Commercial Wines. <i>Journal of Agricultural and Food Chemistry</i> , 1995, 43, 1245-1250.	2.4	95
814	Influences of viticultural and oenological factors on changes in <i>cis</i> - and <i>trans</i> -resveratrol in commercial wines. <i>Journal of Wine Research</i> , 1995, 6, 107-121.	0.9	46
815	The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: Implications for protection against coronary heart disease. <i>Clinica Chimica Acta</i> , 1995, 235, 207-219.	0.5	819
816	Clinical applications of the p53 tumor suppressor gene. <i>Clinica Chimica Acta</i> , 1995, 237, 79-90.	0.5	11
817	Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique. <i>Journal of Urology</i> , 1995, 153, 1004-1008.	0.2	94
818	Detection of Lanthanide Chelates and Multiple Labeling Strategies Based on Time-Resolved Fluorescence. , 1995, , 377-390.		2
819	Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 1994, 32, 291-300.	1.1	101
820	Detection of prostate-specific antigen immunoreactivity in breast tumors. <i>Breast Cancer Research and Treatment</i> , 1994, 32, 301-310.	1.1	132
821	Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1994, 30, 179-195.	1.1	11
822	Variable selectivity of the hitachi chemistry analyzer chloride Ion-selective electrode toward interfering ions. <i>Clinical Biochemistry</i> , 1994, 27, 37-41.	0.8	24
823	Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. <i>Clinical Biochemistry</i> , 1994, 27, 75-79.	0.8	178
824	Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. <i>International Journal of Cancer</i> , 1994, 58, 480-487.	2.3	207
825	Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. <i>Journal of Clinical Laboratory Analysis</i> , 1994, 8, 251-253.	0.9	31
826	Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. <i>Kidney International</i> , 1994, 46, 216-222.	2.6	131
827	Direct injection gas chromatographic mass spectrometric assay for trans-resveratrol. <i>Analytical Chemistry</i> , 1994, 66, 3959-3963.	3.2	81
828	Evaluation of nonisotopic labeling and detection techniques for nucleic acid hybridization. <i>Journal of Clinical Laboratory Analysis</i> , 1993, 7, 174-179.	0.9	3

#	ARTICLE	IF	CITATIONS
829	Time-resolved fluorometry in nucleic acid hybridization and Western blotting techniques. <i>Electrophoresis</i> , 1993, 14, 866-875.	1.3	14
830	Quantification of polymerase chain reaction products in agarose gels with a fluorescent europium chelate as label and time-resolved fluorescence spectroscopy. <i>Analytical Chemistry</i> , 1993, 65, 158-163.	3.2	28
831	Oncogenes and Tumor Suppressor Genes: New Biochemical Tests. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 1992, 29, 269-305.	2.7	16
832	Europium and terbium chelators as candidate substrates for enzyme-labelled time-resolved fluorimetric immunoassays. <i>Analyst, The</i> , 1992, 117, 1879.	1.7	47
833	Enzymically amplified time-resolved fluorescence immunoassay with terbium chelates. <i>Analytical Chemistry</i> , 1992, 64, 342-346.	3.2	193
834	Quantitative Western blot analysis and spot immunodetection using time-resolved fluorometry. <i>Journal of Immunological Methods</i> , 1992, 147, 251-259.	0.6	23
835	Antibodies to the p53 tumor suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique. <i>Clinical Biochemistry</i> , 1992, 25, 445-449.	0.8	22
836	An enzymatic method for measuring serum mannitol and its use in hemodialysis patients. <i>Clinical Biochemistry</i> , 1992, 25, 457-462.	0.8	7
837	Detection of Lanthanide Chelates and Multiple Labeling Strategies Based on Time-Resolved Fluorescence. , 1992, , 263-274.		1
838	Ultrasensitive determination of europium using microsecond time-resolved spectrofluorimetry. <i>Analyst, The</i> , 1991, 116, 627.	1.7	9
839	Quantification of nucleic acids on nitrocellulose membranes with time-resolved fluorometry. <i>Nucleic Acids Research</i> , 1991, 19, 6015-6019.	6.5	27
840	TIME-RESOLVED FLUOROMETRY WITH LANTHANIDE CHELATES AS LABELS-PRINCIPLES, APPLICATIONS AND NEW DEVELOPMENTS. <i>Analytical Sciences</i> , 1991, 7, 785-787.	0.8	3
841	Ultrasensitive Time-Resolved Immunofluorometry of Human Albumin in Urine Using Monoclonal Antibodies—A New Assay for Microalbuminuria. <i>Annals of Clinical Biochemistry</i> , 1990, 27, 232-237.	0.8	4
842	Detection techniques for immunoassay and DNA probing applications. <i>Clinical Biochemistry</i> , 1990, 23, 437-443.	0.8	14
843	Ultrasensitive Time-Resolved Fluorescence Method for $\hat{\pm}$ -Fetoprotein. <i>Clinical Chemistry</i> , 1990, 36, 1497-1502.	1.5	44
844	Analytical methodology for immunoassays and DNA hybridization assays " current status and selected systems " critical review. <i>Clinica Chimica Acta</i> , 1990, 194, 19-50.	0.5	40
845	Streptavidin-based macromolecular complex labeled with a europium chelator suitable for time-resolved fluorescence immunoassay applications. <i>Analytical Chemistry</i> , 1990, 62, 1841-1845.	3.2	78
846	Time-Resolved Immunofluorometric Assay for Thyroxine-Binding Globulin in Serum. <i>Journal of Immunoassay</i> , 1989, 10, 413-428.	0.3	3

#	ARTICLE	IF	CITATIONS
847	Digoxin Immunoassay with Monoclonal and Polyclonal Antibodies Using Time-Resolved Fluorometry. <i>Journal of Pharmaceutical Sciences</i> , 1989, 78, 617-621.	1.6	10
848	Sensitive time-resolved immunofluorometric assay of thyrotropin in serum. <i>Clinical Biochemistry</i> , 1989, 22, 23-29.	0.8	11
849	A double monoclonal time-resolved immunofluorometric assay of carcinoembryonic antigen in serum. <i>Clinical Biochemistry</i> , 1989, 22, 433-438.	0.8	5
850	Multiple fluorescence labeling with europium chelators. Application to time-resolved fluoroimmunoassays. <i>Analytical Chemistry</i> , 1989, 61, 48-53.	3.2	98
851	A Simple Time-Resolved Fluoroimmunoassay of Total Thyroxine in Serum. <i>Annals of Clinical Biochemistry</i> , 1989, 26, 238-243.	0.8	7
852	Immunoassays with time-resolved fluorescence spectroscopy: Principles and applications. <i>Clinical Biochemistry</i> , 1988, 21, 139-150.	0.8	178
853	A new europium chelate for protein labelling and time-resolved fluorometric applications. <i>Clinical Biochemistry</i> , 1988, 21, 173-178.	0.8	190
854	Selective determination of urinary free cortisol by liquid chromatography after solid-state extraction. <i>Biomedical Applications</i> , 1988, 426, 25-32.	1.7	18
855	Time-resolved fluoroimmunoassay of cortisol in serum with a europium chelate as label. <i>Clinical Biochemistry</i> , 1988, 21, 291-296.	0.8	29
856	Immunoassays with time-resolved fluorescence spectroscopy: Principles and applications. <i>Clinical Biochemistry</i> , 1988, 21, 139-150.	0.8	239
857	Laser-excited time-resolved solid-phase fluoroimmunoassays with the new europium chelate 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid as label. <i>Analytical Chemistry</i> , 1988, 60, 1069-1074.	3.2	40
858	A sensitive time-resolved immunofluorometric assay of ferritin in serum with monoclonal antibodies. <i>Clinica Chimica Acta</i> , 1988, 175, 267-275.	0.5	11
859	Time-resolved fluorescence using a europium chelate of 4,7-bis-(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA). <i>Journal of Immunological Methods</i> , 1988, 112, 43-52.	0.6	57
860	Titrimetric determination of iodide, hexacyanoferrate(ii), thiourea, cationic surfactants, and of picrate with a picrate ion-selective electrode. <i>Mikrochimica Acta</i> , 1980, 74, 27-38.	2.5	11
861	Fourth International SAC Conference. Proceedings of the Analytical Division of the Chemical Society, 1978, 15, 78.	0.2	3
862	Titrimetric determination of thiourea and silver with a picrate ion selective electrode. <i>Mikrochimica Acta</i> , 1977, 68, 255-260.	2.5	8
863	Semen biomarker TEX101 predicts sperm retrieval success for men with testicular failure. <i>F1000Research</i> , 0, 10, 569.	0.8	9
864	Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome. , 0, .		6

#	ARTICLE	IF	CITATIONS
865	To Screen or Not to Screen?. , 0, , 349-354.		0